{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:56:58Z","timestamp":1793649418850,"version":"4.5.1"},"reference-count":372,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2024YFFK0343"],"award-info":[{"award-number":["2024YFFK0343"]}]},{"name":"National Key Research and Development Program of China","award":["2024YFB3311700"],"award-info":[{"award-number":["2024YFB3311700"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02472-x","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:33:47Z","timestamp":1761046427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Targeting proteostasis for cancer therapy: current advances, challenges, and future perspectives"],"prefix":"10.1186","volume":"24","author":[{"given":"Chenliang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jielang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiulin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"7","key":"2472_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41580-019-0101-y","volume":"20","author":"MS Hipp","year":"2019","unstructured":"Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol. 2019;20(7):421\u201335.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2472_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.12703\/r\/10-72","volume":"10","author":"K Verma","year":"2021","unstructured":"Verma K, Verma M, Chaphalkar A, Chakraborty K. Recent advances in understanding the role of proteostasis. Fac Rev. 2021;10:72.","journal-title":"Fac Rev"},{"issue":"8","key":"2472_CR3","doi-asserted-by":"publisher","first-page":"17193","DOI":"10.3390\/ijms160817193","volume":"16","author":"JF D\u00edaz-Villanueva","year":"2015","unstructured":"D\u00edaz-Villanueva JF, D\u00edaz-Molina R, Garc\u00eda-Gonz\u00e1lez V. Protein folding and mechanisms of proteostasis. Int J Mol Sci. 2015;16(8):17193\u2013230.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2472_CR4","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1007\/s12035-018-1334-z","volume":"56","author":"A Kurtishi","year":"2019","unstructured":"Kurtishi A, Rosen B, Patil KS, Alves GW, M\u00f8ller SG. Cellular proteostasis in neurodegeneration. Mol Neurobiol. 2019;56(5):3676\u201389.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"2472_CR5","doi-asserted-by":"publisher","first-page":"C93","DOI":"10.1152\/ajpcell.00266.2016","volume":"312","author":"SA Oakes","year":"2017","unstructured":"Oakes SA. Endoplasmic reticulum proteostasis: a key checkpoint in cancer. Am J Physiol Cell Physiol. 2017;312(2):C93\u2013102.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"2472_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.tcb.2015.10.011","volume":"26","author":"C Dai","year":"2016","unstructured":"Dai C, Sampson SB. HSF1: guardian of proteostasis in cancer. Trends Cell Biol. 2016;26(1):17\u201328.","journal-title":"Trends Cell Biol"},{"issue":"6","key":"2472_CR7","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0254-1","volume":"20","author":"P Bastola","year":"2018","unstructured":"Bastola P, Oien DB, Cooley M, Chien J. Emerging cancer therapeutic targets in protein homeostasis. AAPS J. 2018;20(6):94.","journal-title":"AAPS J"},{"key":"2472_CR8","doi-asserted-by":"crossref","unstructured":"Guang MHZ, Kavanagh EL, Dunne LP, et al. Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. Cancers (Basel). 2019;11(1):66.","DOI":"10.3390\/cancers11010066"},{"issue":"12","key":"2472_CR9","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.18632\/aging.101721","volume":"10","author":"AS Anisimova","year":"2018","unstructured":"Anisimova AS, Alexandrov AI, Makarova NE, Gladyshev VN, Dmitriev SE. Protein synthesis and quality control in aging. Aging (Albany NY). 2018;10(12):4269\u201388.","journal-title":"Aging (Albany NY)"},{"issue":"6968","key":"2472_CR10","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/nature02261","volume":"426","author":"CM Dobson","year":"2003","unstructured":"Dobson CM. Protein folding and misfolding. Nature. 2003;426(6968):884\u201390.","journal-title":"Nature"},{"key":"2472_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-biochem-060208-092442","volume":"82","author":"YE Kim","year":"2013","unstructured":"Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU. Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem. 2013;82:323\u201355.","journal-title":"Annu Rev Biochem"},{"issue":"Suppl 1","key":"2472_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","volume":"29","author":"J Adams","year":"2003","unstructured":"Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003;29(Suppl 1):3\u20139.","journal-title":"Cancer Treat Rev"},{"key":"2472_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-58971-4_1","volume":"96","author":"Y Mao","year":"2021","unstructured":"Mao Y. Structure, dynamics and function of the 26S proteasome. Subcell Biochem. 2021;96:1\u2013151.","journal-title":"Subcell Biochem"},{"issue":"1","key":"2472_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bbamcr.2013.05.008","volume":"1843","author":"J Erales","year":"2014","unstructured":"Erales J, Coffino P. Ubiquitin-independent proteasomal degradation. Biochim Biophys Acta. 2014;1843(1):216\u201321.","journal-title":"Biochim Biophys Acta"},{"issue":"3\u20134","key":"2472_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0300-9084(01)01250-0","volume":"83","author":"KJ Davies","year":"2001","unstructured":"Davies KJ. Degradation of oxidized proteins by the 20S proteasome. Biochimie. 2001;83(3\u20134):301\u201310.","journal-title":"Biochimie"},{"issue":"11","key":"2472_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115637","volume":"25","author":"P Wen","year":"2024","unstructured":"Wen P, Sun Y, Jiang TX, Qiu XB. PA200-mediated proteasomal protein degradation and regulation of cellular senescence. Int J Mol Sci. 2024;25(11):5637.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2472_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/biom4020566","volume":"4","author":"P Cascio","year":"2014","unstructured":"Cascio P. PA28\u03b1\u03b2: the enigmatic magic ring of the proteasome? Biomolecules. 2014;4(2):566\u201384.","journal-title":"Biomolecules."},{"issue":"2","key":"2472_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biom11020228","volume":"11","author":"P Cascio","year":"2021","unstructured":"Cascio P. Pa28\u03b3: new insights on an ancient proteasome activator. Biomolecules. 2021;11(2):228.","journal-title":"Biomolecules"},{"key":"2472_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-biochem-061516-044859","volume":"86","author":"A Varshavsky","year":"2017","unstructured":"Varshavsky A. The ubiquitin system, autophagy, and regulated protein degradation. Annu Rev Biochem. 2017;86:123\u20138.","journal-title":"Annu Rev Biochem"},{"issue":"6","key":"2472_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ncb2979","volume":"16","author":"A Stolz","year":"2014","unstructured":"Stolz A, Ernst A, Dikic I. Cargo recognition and trafficking in selective autophagy. Nat Cell Biol. 2014;16(6):495\u2013501.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2472_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/cr.2013.153","volume":"24","author":"AM Cuervo","year":"2014","unstructured":"Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and aging. Cell Res. 2014;24(1):92\u2013104.","journal-title":"Cell Res"},{"issue":"8","key":"2472_CR22","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.bbamcr.2013.12.011","volume":"1843","author":"KE Bonnington","year":"2014","unstructured":"Bonnington KE, Kuehn MJ. Protein selection and export via outer membrane vesicles. Biochim Biophys Acta. 2014;1843(8):1612\u20139.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2472_CR23","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1038\/s41467-025-57408-2","volume":"16","author":"V Malhotra","year":"2025","unstructured":"Malhotra V. The pathways of secretory cargo export at the endoplasmic reticulum. Nat Commun. 2025;16(1):2138.","journal-title":"Nat Commun."},{"issue":"29","key":"2472_CR24","doi-asserted-by":"publisher","first-page":"11988","DOI":"10.1073\/pnas.1310230110","volume":"110","author":"M Pourdehnad","year":"2013","unstructured":"Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A. 2013;110(29):11988\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2472_CR25","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1172\/JCI70198","volume":"124","author":"M Grzmil","year":"2014","unstructured":"Grzmil M, Huber RM, Hess D, et al. MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas. J Clin Invest. 2014;124(2):742\u201354.","journal-title":"J Clin Invest"},{"issue":"1","key":"2472_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8(1):455.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2472_CR27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s43018-020-0085-8","volume":"1","author":"Y Fu","year":"2020","unstructured":"Fu Y, Jung AW, Torne RV, et al. Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis. Nat Cancer. 2020;1(8):800\u201310.","journal-title":"Nat Cancer"},{"issue":"3","key":"2472_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nrg3123","volume":"13","author":"DJ Gordon","year":"2012","unstructured":"Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet. 2012;13(3):189\u2013203.","journal-title":"Nat Rev Genet"},{"key":"2472_CR29","doi-asserted-by":"crossref","unstructured":"Muhammad B, Parks LG, Komurov K, Privette Vinnedge LM. Defective transcription elongation in human cancers imposes targetable proteotoxic vulnerability. Transl Oncol. 2022;16.","DOI":"10.1016\/j.tranon.2021.101323"},{"issue":"11","key":"2472_CR30","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1158\/1541-7786.MCR-05-0221","volume":"3","author":"DE Feldman","year":"2005","unstructured":"Feldman DE, Chauhan V, Koong AC. The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res. 2005;3(11):597\u2013605.","journal-title":"Mol Cancer Res"},{"key":"2472_CR31","doi-asserted-by":"crossref","unstructured":"Sannino S, Manuel AM, Shang C, Wendell SG, Wipf P, Brodsky JL. Non-Essential Amino Acid Availability Influences Proteostasis and Breast Cancer Cell Survival During Proteotoxic Stress. Mol Cancer Res. 2023;21(7):675\u2013690.","DOI":"10.1158\/1541-7786.MCR-22-0843"},{"issue":"8","key":"2472_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084209","volume":"25","author":"MK Singh","year":"2024","unstructured":"Singh MK, Shin Y, Ju S, et al. Heat shock response and heat shock proteins: current understanding and future opportunities in human diseases. Int J Mol Sci. 2024;25(8):4209.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2472_CR33","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1096\/fj00-0294rev","volume":"15","author":"L Pirkkala","year":"2001","unstructured":"Pirkkala L, Nyk\u00e4nen P, Sistonen L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J. 2001;15(7):1118\u201331.","journal-title":"FASEB J"},{"issue":"2","key":"2472_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nsmb.3165","volume":"23","author":"A Nakai","year":"2016","unstructured":"Nakai A. Molecular basis of HSF regulation. Nat Struct Mol Biol. 2016;23(2):93\u20135.","journal-title":"Nat Struct Mol Biol"},{"issue":"45","key":"2472_CR35","doi-asserted-by":"publisher","first-page":"18378","DOI":"10.1073\/pnas.1115031108","volume":"108","author":"S Santagata","year":"2011","unstructured":"Santagata S, Hu R, Lin NU, et al. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A. 2011;108(45):18378\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"2472_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70157","volume":"13","author":"Y Liu","year":"2024","unstructured":"Liu Y, Shi Q, Su Y, Chen Z, He X. Heat shock transcription factor 1 facilitates liver cancer progression by driving super-enhancer-mediated transcription of MYCN. Cancer Med. 2024;13(17):e70157.","journal-title":"Cancer Med"},{"issue":"2","key":"2472_CR37","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.athoracsur.2015.03.021","volume":"100","author":"J Cui","year":"2015","unstructured":"Cui J, Tian H, Chen G. Upregulation of nuclear heat shock factor 1 contributes to tumor angiogenesis and poor survival in patients with Non-Small cell lung cancer. Ann Thorac Surg. 2015;100(2):465\u201372.","journal-title":"Ann Thorac Surg"},{"issue":"58","key":"2472_CR38","doi-asserted-by":"publisher","first-page":"31200","DOI":"10.18632\/oncotarget.25756","volume":"9","author":"JK Bj\u00f6rk","year":"2018","unstructured":"Bj\u00f6rk JK, Ahonen I, Mirtti T, et al. Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy. Oncotarget. 2018;9(58):31200\u201313.","journal-title":"Oncotarget"},{"issue":"1","key":"2472_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13046-017-0537-x","volume":"36","author":"W Liang","year":"2017","unstructured":"Liang W, Liao Y, Zhang J, et al. Heat shock factor 1 inhibits the mitochondrial apoptosis pathway by regulating second mitochondria-derived activator of caspase to promote pancreatic tumorigenesis. J Exp Clin Cancer Res. 2017;36(1):64.","journal-title":"J Exp Clin Cancer Res"},{"key":"2472_CR40","doi-asserted-by":"crossref","unstructured":"Chou SD, Prince T, Gong J, Calderwood SK. mTOR is essential for the proteotoxic stress response, HSF1 activation and heat shock protein synthesis. PLoS One. 2012;7(6):e39679.","DOI":"10.1371\/journal.pone.0039679"},{"issue":"13","key":"2472_CR41","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1111\/febs.16375","volume":"289","author":"WC Lu","year":"2022","unstructured":"Lu WC, Omari R, Ray H, et al. AKT1 mediates multiple phosphorylation events that functionally promote HSF1 activation. FEBS J. 2022;289(13):3876\u201393.","journal-title":"FEBS J"},{"issue":"4","key":"2472_CR42","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cell.2015.01.028","volume":"160","author":"Z Tang","year":"2015","unstructured":"Tang Z, Dai S, He Y, et al. MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1. Cell. 2015;160(4):729\u201344.","journal-title":"Cell"},{"issue":"5","key":"2472_CR43","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s12192-013-0413-3","volume":"18","author":"A Finka","year":"2013","unstructured":"Finka A, Goloubinoff P. Proteomic data from human cell cultures refine mechanisms of chaperone-mediated protein homeostasis. Cell Stress Chaperones. 2013;18(5):591\u2013605.","journal-title":"Cell Stress Chaperones"},{"issue":"11","key":"2472_CR44","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","volume":"43","author":"J Park","year":"2020","unstructured":"Park J, Cho J, Song EJ. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res. 2020;43(11):1144\u201361.","journal-title":"Arch Pharm Res"},{"issue":"6","key":"2472_CR45","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/embor.2008.93","volume":"9","author":"F Ikeda","year":"2008","unstructured":"Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. EMBO Rep. 2008;9(6):536\u201342.","journal-title":"EMBO Rep"},{"key":"2472_CR46","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.biochem.70.1.503","volume":"70","author":"CM Pickart","year":"2001","unstructured":"Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503\u201333.","journal-title":"Annu Rev Biochem"},{"issue":"Pt 2","key":"2472_CR47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1242\/jcs.090985","volume":"125","author":"MJ Clague","year":"2012","unstructured":"Clague MJ, Coulson JM, Urb\u00e9 S. Cellular functions of the DUBs. J Cell Sci. 2012;125(Pt 2):277\u201386.","journal-title":"J Cell Sci"},{"issue":"4","key":"2472_CR48","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36(4):561\u201384.","journal-title":"Cancer Metastasis Rev"},{"issue":"45","key":"2472_CR49","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1038\/onc.2009.264","volume":"28","author":"A Arlt","year":"2009","unstructured":"Arlt A, Bauer I, Schafmayer C, et al. Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene. 2009;28(45):3983\u201396.","journal-title":"Oncogene"},{"key":"2472_CR50","doi-asserted-by":"crossref","unstructured":"Ivanova EV, Kondakova IV, Spirina LV, Afanas\u2019ev SG, Avgustinovich AV, Cheremisina OV. Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. Bull Exp Biol Med. 2014;157(6):781\u2013784.","DOI":"10.1007\/s10517-014-2666-y"},{"issue":"13","key":"2472_CR51","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1158\/0008-5472.CAN-05-0201","volume":"65","author":"L Chen","year":"2005","unstructured":"Chen L, Madura K. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res. 2005;65(13):5599\u2013606.","journal-title":"Cancer Res"},{"issue":"21","key":"2472_CR52","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.1158\/1078-0432.CCR-15-1945","volume":"22","author":"K Munakata","year":"2016","unstructured":"Munakata K, Uemura M, Tanaka S, et al. Cancer stem-like properties in colorectal cancer cells with low proteasome activity. Clin Cancer Res. 2016;22(21):5277\u201386.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2472_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013298","volume":"5","author":"J Pan","year":"2010","unstructured":"Pan J, Zhang Q, Wang Y, You M. 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. PLoS One. 2010;5(10):e13298.","journal-title":"PLoS One"},{"issue":"8","key":"2472_CR54","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/ncb0805-766","volume":"7","author":"B Meusser","year":"2005","unstructured":"Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol. 2005;7(8):766\u201372.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"2472_CR55","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ceb.2010.10.002","volume":"23","author":"R Bernasconi","year":"2011","unstructured":"Bernasconi R, Molinari M. ERAD and ERAD tuning: disposal of cargo and of ERAD regulators from the mammalian ER. Curr Opin Cell Biol. 2011;23(2):176\u201383.","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"2472_CR56","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.bbamcr.2011.07.001","volume":"1823","author":"K Yamanaka","year":"2012","unstructured":"Yamanaka K, Sasagawa Y, Ogura T. Recent advances in p97\/VCP\/Cdc48 cellular functions. Biochim Biophys Acta. 2012;1823(1):130\u20137.","journal-title":"Biochim Biophys Acta"},{"issue":"Pt 7","key":"2472_CR57","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1242\/jcs.035832","volume":"123","author":"PI Merksamer","year":"2010","unstructured":"Merksamer PI, Papa FR. The UPR and cell fate at a glance. J Cell Sci. 2010;123(Pt 7):1003\u20136.","journal-title":"J Cell Sci"},{"key":"2472_CR58","doi-asserted-by":"crossref","unstructured":"Harding HP, Zhang Y, Bertolotti A, Zeng H, Ron D. Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell. 2000;5(5):897\u2013904.","DOI":"10.1016\/S1097-2765(00)80330-5"},{"issue":"7","key":"2472_CR59","doi-asserted-by":"publisher","first-page":"723","DOI":"10.4161\/cbt.5.7.2967","volume":"5","author":"DR Fels","year":"2006","unstructured":"Fels DR, Koumenis C. The PERK\/eIF2alpha\/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol Ther. 2006;5(7):723\u20138.","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"2472_CR60","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1083\/jcb.153.5.1011","volume":"153","author":"I Novoa","year":"2001","unstructured":"Novoa I, Zeng H, Harding HP, Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol. 2001;153(5):1011\u201322.","journal-title":"J Cell Biol"},{"issue":"7","key":"2472_CR61","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0092-8674(01)00611-0","volume":"107","author":"H Yoshida","year":"2001","unstructured":"Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001;107(7):881\u201391.","journal-title":"Cell"},{"issue":"5","key":"2472_CR62","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tibs.2014.02.008","volume":"39","author":"M Maurel","year":"2014","unstructured":"Maurel M, Chevet E, Tavernier J, Gerlo S. Getting RIDD of RNA: IRE1 in cell fate regulation. Trends Biochem Sci. 2014;39(5):245\u201354.","journal-title":"Trends Biochem Sci"},{"issue":"33","key":"2472_CR63","doi-asserted-by":"publisher","first-page":"31024","DOI":"10.1074\/jbc.M300923200","volume":"278","author":"T Okada","year":"2003","unstructured":"Okada T, Haze K, Nadanaka S, et al. A serine protease inhibitor prevents endoplasmic reticulum stress-induced cleavage but not transport of the membrane-bound transcription factor ATF6. J Biol Chem. 2003;278(33):31024\u201332.","journal-title":"J Biol Chem"},{"issue":"6","key":"2472_CR64","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/S1097-2765(00)00133-7","volume":"6","author":"J Ye","year":"2000","unstructured":"Ye J, Rawson RB, Komuro R, et al. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell. 2000;6(6):1355\u201364.","journal-title":"Mol Cell"},{"issue":"35","key":"2472_CR65","doi-asserted-by":"publisher","first-page":"27013","DOI":"10.1016\/S0021-9258(19)61473-0","volume":"275","author":"Y Wang","year":"2000","unstructured":"Wang Y, Shen J, Arenzana N, Tirasophon W, Kaufman RJ, Prywes R. Activation of ATF6 and an ATF6 DNA binding site by the endoplasmic reticulum stress response. J Biol Chem. 2000;275(35):27013\u201320.","journal-title":"J Biol Chem"},{"issue":"1","key":"2472_CR66","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1247\/csf.07044","volume":"33","author":"Y Adachi","year":"2008","unstructured":"Adachi Y, Yamamoto K, Okada T, Yoshida H, Harada A, Mori K. ATF6 is a transcription factor specializing in the regulation of quality control proteins in the endoplasmic reticulum. Cell Struct Funct. 2008;33(1):75\u201389.","journal-title":"Cell Struct Funct"},{"issue":"3","key":"2472_CR67","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.devcel.2007.07.018","volume":"13","author":"K Yamamoto","year":"2007","unstructured":"Yamamoto K, Sato T, Matsui T, et al. Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. Dev Cell. 2007;13(3):365\u201376.","journal-title":"Dev Cell."},{"issue":"6","key":"2472_CR68","first-page":"2627","volume":"12","author":"M Oshi","year":"2022","unstructured":"Oshi M, Roy AM, Gandhi S, et al. The clinical relevance of unfolded protein response signaling in breast cancer. Am J Cancer Res. 2022;12(6):2627\u201340.","journal-title":"Am J Cancer Res."},{"issue":"2","key":"2472_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020261","volume":"13","author":"CM Robinson","year":"2021","unstructured":"Robinson CM, Talty A, Logue SE, Mnich K, Gorman AM, Samali A. An emerging role for the unfolded protein response in pancreatic cancer. Cancers (Basel). 2021;13(2):261.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2472_CR70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00018-022-04143-2","volume":"79","author":"S Su","year":"2022","unstructured":"Su S, Shi YT, Chu Y, et al. Section 62 promotes gastric cancer metastasis through mediating UPR-induced autophagy activation. Cell Mol Life Sci. 2022;79(2):133.","journal-title":"Cell Mol Life Sci."},{"issue":"1","key":"2472_CR71","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0447-0","volume":"32","author":"X Shen","year":"2015","unstructured":"Shen X, Xue Y, Si Y, et al. The unfolded protein response potentiates epithelial-to-mesenchymal transition (EMT) of gastric cancer cells under severe hypoxic conditions. Med Oncol. 2015;32(1):447.","journal-title":"Med Oncol"},{"issue":"17","key":"2472_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174443","volume":"13","author":"A Patel","year":"2021","unstructured":"Patel A, Oshi M, Yan L, Matsuyama R, Endo I, Takabe K. The unfolded protein response is associated with cancer proliferation and worse survival in hepatocellular carcinoma. Cancers (Basel). 2021;13(17):4443.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2472_CR73","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/pros.23264","volume":"77","author":"J Liu","year":"2017","unstructured":"Liu J, Xiao M, Li J, et al. Activation of UPR signaling pathway is associated with the malignant progression and poor prognosis in prostate cancer. Prostate. 2017;77(3):274\u201381.","journal-title":"Prostate"},{"issue":"470","key":"2472_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aal2323","volume":"10","author":"J Obacz","year":"2017","unstructured":"Obacz J, Avril T, Le Reste PJ, et al. Endoplasmic reticulum proteostasis in glioblastoma-from molecular mechanisms to therapeutic perspectives. Sci Signal. 2017;10(470):eaal2323.","journal-title":"Sci Signal"},{"issue":"1","key":"2472_CR75","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12072-014-9582-0","volume":"9","author":"YP Vandewynckel","year":"2014","unstructured":"Vandewynckel YP, Laukens D, Bogaerts E, et al. Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy. Hepatol Int. 2014;9(1):93\u2013104.","journal-title":"Hepatol Int."},{"issue":"6489","key":"2472_CR76","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat5314","volume":"368","author":"M Costa-Mattioli","year":"2020","unstructured":"Costa-Mattioli M, Walter P. The integrated stress response: from mechanism to disease. Science. 2020;368(6489):eaat5314.","journal-title":"Science"},{"key":"2472_CR77","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.77780","volume":"11","author":"B Hurwitz","year":"2022","unstructured":"Hurwitz B, Guzzi N, Gola A, et al. The integrated stress response remodels the microtubule-organizing center to clear unfolded proteins following proteotoxic stress. Elife. 2022;11:e77780.","journal-title":"Elife"},{"issue":"10","key":"2472_CR78","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.260888","volume":"136","author":"B Bauer","year":"2023","unstructured":"Bauer B, Martens S, Ferrari L. Aggrephagy at a glance. J Cell Sci. 2023;136(10):jcs260888.","journal-title":"J Cell Sci"},{"issue":"16","key":"2472_CR79","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.devcel.2024.07.004","volume":"59","author":"C De Leonibus","year":"2024","unstructured":"De Leonibus C, Maddaluno M, Ferriero R, et al. Sestrin2 drives ER-phagy in response to protein misfolding. Dev Cell. 2024;59(16):2035-2052.e10.","journal-title":"Dev Cell."},{"issue":"15","key":"2472_CR80","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/1873-3468.14674","volume":"597","author":"M Rudinskiy","year":"2023","unstructured":"Rudinskiy M, Molinari M. ER-to-lysosome-associated degradation in a nutshell: mammalian, yeast, and plant ER-phagy as induced by misfolded proteins. FEBS Lett. 2023;597(15):1928\u201345.","journal-title":"FEBS Lett"},{"key":"2472_CR81","doi-asserted-by":"crossref","unstructured":"Solvik TA, Nguyen TA, Tony Lin YH, et al. Secretory autophagy maintains proteostasis upon lysosome inhibition. J Cell Biol. 2022;221(6).","DOI":"10.1083\/jcb.202110151"},{"issue":"31","key":"2472_CR82","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1038\/onc.2010.191","volume":"29","author":"T Rzymski","year":"2010","unstructured":"Rzymski T, Milani M, Pike L, et al. Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene. 2010;29(31):4424\u201335.","journal-title":"Oncogene"},{"issue":"1","key":"2472_CR83","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1172\/JCI40027","volume":"120","author":"KM Rouschop","year":"2010","unstructured":"Rouschop KM, van den Beucken T, Dubois L, et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest. 2010;120(1):127\u201341.","journal-title":"J Clin Invest."},{"issue":"16","key":"2472_CR84","doi-asserted-by":"publisher","first-page":"7683","DOI":"10.1093\/nar\/gkt563","volume":"41","author":"W B\u2019chir","year":"2013","unstructured":"B\u2019chir W, Maurin AC, Carraro V, et al. The eIF2\u03b1\/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res. 2013;41(16):7683\u201399.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2472_CR85","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4161\/auto.23486","volume":"9","author":"S Dey","year":"2013","unstructured":"Dey S, Tameire F, Koumenis C. PERK-ing up autophagy during MYC-induced tumorigenesis. Autophagy. 2013;9(4):612\u20134.","journal-title":"Autophagy"},{"issue":"12","key":"2472_CR86","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1172\/JCI62973","volume":"122","author":"LS Hart","year":"2012","unstructured":"Hart LS, Cunningham JT, Datta T, et al. Er stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest. 2012;122(12):4621\u201334.","journal-title":"J Clin Invest"},{"issue":"12","key":"2472_CR87","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907\u201316.","journal-title":"Blood"},{"issue":"19","key":"2472_CR88","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1093\/hmg\/ddi312","volume":"14","author":"V Men\u00e9ndez-Benito","year":"2005","unstructured":"Men\u00e9ndez-Benito V, Verhoef LG, Masucci MG, Dantuma NP. Endoplasmic reticulum stress compromises the ubiquitin-proteasome system. Hum Mol Genet. 2005;14(19):2787\u201399.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2472_CR89","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3892\/mmr.2015.4599","volume":"13","author":"W Bao","year":"2016","unstructured":"Bao W, Gu Y, Ta L, Wang K, Xu Z. Induction of autophagy by the MG\u2013132 proteasome inhibitor is associated with endoplasmic reticulum stress in MCF\u20137 cells. Mol Med Rep. 2016;13(1):796\u2013804.","journal-title":"Mol Med Rep"},{"key":"2472_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2018.00128","volume":"6","author":"NM Kocaturk","year":"2018","unstructured":"Kocaturk NM, Gozuacik D. Crosstalk between mammalian autophagy and the ubiquitin-proteasome system. Front Cell Dev Biol. 2018;6:128.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"2472_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092385","volume":"12","author":"C Brancolini","year":"2020","unstructured":"Brancolini C, Iuliano L. Proteotoxic stress and cell death in cancer cells. Cancers (Basel). 2020;12(9):2385.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2472_CR92","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/cdd.2017.53","volume":"24","author":"JA Glab","year":"2017","unstructured":"Glab JA, Doerflinger M, Nedeva C, et al. DR5 and caspase-8 are dispensable in ER stress-induced apoptosis. Cell Death Differ. 2017;24(5):944\u201350.","journal-title":"Cell Death Differ"},{"issue":"10","key":"2472_CR93","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1158\/0008-5472.CAN-06-4274","volume":"67","author":"X Liu","year":"2007","unstructured":"Liu X, Yue P, Chen S, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007;67(10):4981\u20138.","journal-title":"Cancer Res"},{"key":"2472_CR94","doi-asserted-by":"crossref","unstructured":"Law ME, Dulloo ZM, Eggleston SR, et al. DR5 disulfide bonding functions as a sensor and effector of protein folding stress. Mol Cancer Res. Published online March 19, 2024. doi:10.1158\/1541-7786.","DOI":"10.1101\/2024.03.04.583390"},{"key":"2472_CR95","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.52291","volume":"9","author":"M Lam","year":"2020","unstructured":"Lam M, Marsters SA, Ashkenazi A, Walter P. Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress. Elife. 2020;9:e52291.","journal-title":"Elife"},{"issue":"1","key":"2472_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07403-8","volume":"16","author":"F Zappa","year":"2025","unstructured":"Zappa F, Muniozguren NL, Conrad JE, Acosta-Alvear D. The integrated stress response engages a cell-autonomous, ligand-independent, DR5-driven apoptosis switch. Cell Death Dis. 2025;16(1):101.","journal-title":"Cell Death Dis"},{"key":"2472_CR97","doi-asserted-by":"crossref","unstructured":"Puthalakath H, O\u2019Reilly LA, Gunn P, et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell. 2007;129(7):1337\u20131349.","DOI":"10.1016\/j.cell.2007.04.027"},{"issue":"28","key":"2472_CR98","doi-asserted-by":"publisher","first-page":"11792","DOI":"10.1074\/jbc.M117.785113","volume":"292","author":"P Sopha","year":"2017","unstructured":"Sopha P, Ren HY, Grove DE, Cyr DM. Endoplasmic reticulum stress-induced degradation of DNAJB12 stimulates BOK accumulation and primes cancer cells for apoptosis. J Biol Chem. 2017;292(28):11792\u2013803.","journal-title":"J Biol Chem"},{"issue":"3","key":"2472_CR99","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.gendis.2020.06.005","volume":"8","author":"MR Zinatizadeh","year":"2020","unstructured":"Zinatizadeh MR, Schock B, Chalbatani GM, Zarandi PK, Jalali SA, Miri SR. The nuclear factor kappa B (NF-kB) signaling in cancer development and immune diseases. Genes Dis. 2020;8(3):287\u201397.","journal-title":"Genes Dis"},{"issue":"20","key":"2472_CR100","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1182\/blood-2009-09-243402","volume":"115","author":"AM Roccaro","year":"2010","unstructured":"Roccaro AM, Sacco A, Aujay M, et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood. 2010;115(20):4051\u201360.","journal-title":"Blood"},{"key":"2472_CR101","doi-asserted-by":"crossref","unstructured":"Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer. 1998;77(7):1103\u20131107.","DOI":"10.1038\/bjc.1998.183"},{"issue":"1","key":"2472_CR102","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-007-9837-8","volume":"112","author":"J Domingo-Dom\u00e8nech","year":"2008","unstructured":"Domingo-Dom\u00e8nech J, Pippa R, T\u00e1pia M, Gasc\u00f3n P, Bachs O, Bosch M. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat. 2008;112(1):53\u201362.","journal-title":"Breast Cancer Res Treat"},{"key":"2472_CR103","doi-asserted-by":"crossref","unstructured":"Hideshima T, Ikeda H, Chauhan D, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009;114(5):1046\u20131052.","DOI":"10.1182\/blood-2009-01-199604"},{"issue":"5","key":"2472_CR104","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1074\/jbc.M113.502641","volume":"289","author":"B Singha","year":"2014","unstructured":"Singha B, Gatla HR, Manna S, et al. Proteasome inhibition increases recruitment of I\u03baB kinase \u03b2 (IKK\u03b2), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. J Biol Chem. 2014;289(5):2687\u2013700.","journal-title":"J Biol Chem"},{"issue":"3","key":"2472_CR105","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1159\/000490210","volume":"47","author":"GY Yu","year":"2018","unstructured":"Yu GY, Wang X, Zheng SS, et al. RA190, a proteasome subunit ADRM1 inhibitor, suppresses intrahepatic cholangiocarcinoma by inducing NF-KB-mediated cell apoptosis. Cell Physiol Biochem. 2018;47(3):1152\u201366.","journal-title":"Cell Physiol Biochem"},{"key":"2472_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/cddiscovery.2017.59","volume":"3","author":"X Zhu","year":"2017","unstructured":"Zhu X, Huang L, Gong J, et al. NF-\u03baB pathway link with ER stress-induced autophagy and apoptosis in cervical tumor cells. Cell Death Discov. 2017;3:17059.","journal-title":"Cell Death Discov"},{"key":"2472_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-017-0012-7","volume":"4","author":"P Fan","year":"2018","unstructured":"Fan P, Tyagi AK, Agboke FA, Mathur R, Pokharel N, Jordan VC. Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells. Cell Death Discov. 2018;4:15.","journal-title":"Cell Death Discov"},{"issue":"8","key":"2472_CR108","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1002\/1878-0261.12936","volume":"15","author":"M Liu","year":"2021","unstructured":"Liu M, Fan Y, Li D, et al. Ferroptosis inducer erastin sensitizes NSCLC cells to celastrol through activation of the ROS-mitochondrial fission-mitophagy axis. Mol Oncol. 2021;15(8):2084\u2013105.","journal-title":"Mol Oncol"},{"issue":"1","key":"2472_CR109","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00715-1","volume":"14","author":"G Jia","year":"2023","unstructured":"Jia G, Wu W, Chen L, et al. HSF1 is a novel prognostic biomarker in high-risk prostate cancer that correlates with ferroptosis. Discover Oncol. 2023;14(1):107.","journal-title":"Discover Oncol"},{"issue":"9","key":"2472_CR110","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1080\/15548627.2020.1810918","volume":"17","author":"X Chen","year":"2021","unstructured":"Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17(9):2054\u201381.","journal-title":"Autophagy"},{"key":"2472_CR111","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.freeradbiomed.2023.03.027","volume":"202","author":"J Yang","year":"2023","unstructured":"Yang J, Xu H, Wu W, et al. Ferroptosis signaling promotes the release of misfolded proteins via exosomes to rescue ER stress in hepatocellular carcinoma. Free Radic Biol Med. 2023;202:110\u201320.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"2472_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Cao F, Yin HL, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11(2):88.","journal-title":"Cell Death Dis"},{"issue":"2","key":"2472_CR113","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/sj.cdd.4402234","volume":"15","author":"E Ullman","year":"2008","unstructured":"Ullman E, Fan Y, Stawowczyk M, Chen HM, Yue Z, Zong WX. Autophagy promotes necrosis in apoptosis-deficient cells in response to ER stress. Cell Death Differ. 2008;15(2):422\u20135.","journal-title":"Cell Death Differ"},{"issue":"11","key":"2472_CR114","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1074\/jbc.M115.700997","volume":"291","author":"K Moriwaki","year":"2016","unstructured":"Moriwaki K, Chan FK. Regulation of RIPK3- and RHIM-dependent necroptosis by the proteasome. J Biol Chem. 2016;291(11):5948\u201359.","journal-title":"J Biol Chem"},{"issue":"3","key":"2472_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0371-x","volume":"9","author":"M Ali","year":"2018","unstructured":"Ali M, Mocarski ES. Proteasome inhibition blocks necroptosis by attenuating death complex aggregation. Cell Death Dis. 2018;9(3):346.","journal-title":"Cell Death Dis"},{"issue":"7778","key":"2472_CR116","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1548-x","volume":"574","author":"K Newton","year":"2019","unstructured":"Newton K, Wickliffe KE, Dugger DL, et al. Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis. Nature. 2019;574(7778):428\u201331.","journal-title":"Nature"},{"issue":"1","key":"2472_CR117","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.aohep.2019.05.008","volume":"19","author":"RD Tian","year":"2020","unstructured":"Tian RD, Chen YQ, He YH, et al. Phosphorylation of eIF2\u03b1 mitigates endoplasmic reticulum stress and hepatocyte necroptosis in acute liver injury. Ann Hepatol. 2020;19(1):79\u201387.","journal-title":"Ann Hepatol"},{"issue":"10","key":"2472_CR118","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/aps.2016.61","volume":"37","author":"YM Ma","year":"2016","unstructured":"Ma YM, Peng YM, Zhu QH, et al. Novel CHOP activator LGH00168 induces necroptosis in A549 human lung cancer cells via ROS-mediated ER stress and NF-\u03baB inhibition. Acta Pharmacol Sin. 2016;37(10):1381\u201390.","journal-title":"Acta Pharmacol Sin"},{"issue":"1\u20132","key":"2472_CR119","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11010-014-2216-y","volume":"398","author":"R Kr\u0119towski","year":"2015","unstructured":"Kr\u0119towski R, Stypu\u0142kowska A, Cechowska-Pasko M. Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line. Mol Cell Biochem. 2015;398(1\u20132):165\u201373.","journal-title":"Mol Cell Biochem"},{"issue":"22","key":"2472_CR120","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.1158\/0008-5472.CAN-08-2873","volume":"68","author":"DR Fels","year":"2008","unstructured":"Fels DR, Ye J, Segan AT, et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res. 2008;68(22):9323\u201330.","journal-title":"Cancer Res"},{"issue":"2","key":"2472_CR121","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41401-023-01159-7","volume":"45","author":"CC Xu","year":"2024","unstructured":"Xu CC, Lin YF, Huang MY, et al. Paraptosis: a non-classical paradigm of cell death for cancer therapy. Acta Pharmacol Sin. 2024;45(2):223\u201337.","journal-title":"Acta Pharmacol Sin"},{"key":"2472_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156647","volume":"141","author":"WY Lyu","year":"2025","unstructured":"Lyu WY, Cao J, Deng WQ, et al. Xerophenone H, a naturally-derived proteasome inhibitor, triggers apoptosis and paraptosis in lung cancer. Phytomedicine. 2025;141:156647.","journal-title":"Phytomedicine"},{"issue":"1","key":"2472_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05586-6","volume":"14","author":"MJ Seo","year":"2023","unstructured":"Seo MJ, Kim IY, Lee DM, et al. Dual inhibition of thioredoxin reductase and proteasome is required for auranofin-induced paraptosis in breast cancer cells. Cell Death Dis. 2023;14(1):42.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2472_CR124","doi-asserted-by":"publisher","first-page":"e1112","DOI":"10.1038\/cddis.2014.85","volume":"5","author":"MJ Yoon","year":"2014","unstructured":"Yoon MJ, Kang YJ, Lee JA, et al. Stronger proteasomal inhibition and higher CHOP induction are responsible for more effective induction of paraptosis by dimethoxycurcumin than curcumin. Cell Death Dis. 2014;5(3):e1112.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2472_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052648","volume":"23","author":"HJ Lee","year":"2022","unstructured":"Lee HJ, Lee DM, Seo MJ, Kang HC, Kwon SK, Choi KS. PSMD14 targeting triggers paraptosis in breast cancer cells by inducing proteasome inhibition and Ca2\u2009+\u2009imbalance. Int J Mol Sci. 2022;23(5):2648.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"2472_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20246112","volume":"20","author":"AR Lee","year":"2019","unstructured":"Lee AR, Seo MJ, Kim J, et al. Lercanidipine synergistically enhances bortezomib cytotoxicity in cancer cells via enhanced endoplasmic reticulum stress and mitochondrial Ca2\u2009+\u2009overload. Int J Mol Sci. 2019;20(24):6112.","journal-title":"Int J Mol Sci"},{"key":"2472_CR127","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bbrc.2022.01.082","volume":"596","author":"DM Lee","year":"2022","unstructured":"Lee DM, Seo MJ, Lee HJ, Jin HJ, Choi KS. Isrib plus bortezomib triggers paraptosis in breast cancer cells via enhanced translation and subsequent proteotoxic stress. Biochem Biophys Res Commun. 2022;596:56\u201362.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"2472_CR128","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1038\/s44319-024-00248-w","volume":"25","author":"C Zhang","year":"2024","unstructured":"Zhang C, Xu H, Tang Q, et al. CaMKII suppresses proteotoxicity by phosphorylating BAG3 in response to proteasomal dysfunction. EMBO Rep. 2024;25(10):4488\u2013514.","journal-title":"EMBO Rep"},{"issue":"6586","key":"2472_CR129","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254\u201361.","journal-title":"Science"},{"issue":"1","key":"2472_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01589-8","volume":"17","author":"C Zhang","year":"2024","unstructured":"Zhang C, Huang T, Li L. Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives. J Hematol Oncol. 2024;17(1):68.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2472_CR131","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41589-019-0291-9","volume":"15","author":"P Tsvetkov","year":"2019","unstructured":"Tsvetkov P, Detappe A, Cai K, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019;15(7):681\u20139.","journal-title":"Nat Chem Biol"},{"key":"2472_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107579","volume":"213","author":"GR Tundo","year":"2020","unstructured":"Tundo GR, Sbardella D, Santoro AM, et al. The proteasome as a druggable target with multiple therapeutic potentialities: cutting and non-cutting edges. Pharmacol Ther. 2020;213:107579.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"2472_CR133","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","volume":"2","author":"A Field-Smith","year":"2006","unstructured":"Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcadetrade mark) in the treatment of multiple myeloma. Ther Clin Risk Manag. 2006;2(3):271\u20139.","journal-title":"Ther Clin Risk Manag"},{"key":"2472_CR134","doi-asserted-by":"crossref","unstructured":"Chen X, Wu X, Li L, Zhu X. Development of Proteasome Inhibitors for Cancer Therapy. Int J Drug Discov Pharm. 2024; 100004\u2013100004.","DOI":"10.53941\/ijddp.2024.100004"},{"issue":"9","key":"2472_CR135","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","volume":"26","author":"P Roth","year":"2024","unstructured":"Roth P, Gorlia T, Reijneveld JC, et al. Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial. Neuro Oncol. 2024;26(9):1670\u201382.","journal-title":"Neuro Oncol"},{"issue":"9","key":"2472_CR136","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/neuonc\/noae118","volume":"26","author":"SJ Liu","year":"2024","unstructured":"Liu SJ, Raleigh DR, de Groot JF. Proteasome inhibition for glioblastoma: lessons learned and new opportunities. Neuro Oncol. 2024;26(9):1683\u20134.","journal-title":"Neuro Oncol"},{"issue":"9","key":"2472_CR137","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1158\/0008-5472.CAN-05-4529","volume":"66","author":"H Yang","year":"2006","unstructured":"Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese thunder of God vine, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006;66(9):4758\u201365.","journal-title":"Cancer Res"},{"key":"2472_CR138","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ejphar.2019.03.036","volume":"853","author":"YL Zhong","year":"2019","unstructured":"Zhong YL, Xu GJ, Huang S, et al. Celastrol induce apoptosis of human multiple myeloma cells involving inhibition of proteasome activity. Eur J Pharmacol. 2019;853:184\u201392.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"2472_CR139","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3324\/haematol.2014.109421","volume":"100","author":"M Kraus","year":"2015","unstructured":"Kraus M, Bader J, Geurink PP, et al. The novel \u03b22-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica. 2015;100(10):1350\u201360.","journal-title":"Haematologica"},{"issue":"12","key":"2472_CR140","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.4161\/cc.8.12.8798","volume":"8","author":"A Kazi","year":"2009","unstructured":"Kazi A, Lawrence H, Guida WC, et al. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle. 2009;8(12):1940\u201351.","journal-title":"Cell Cycle"},{"key":"2472_CR141","doi-asserted-by":"crossref","unstructured":"Wang X, D\u2019Arcy P, Caulfield TR, et al. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Chem Biol Drug Des. 2015;86(5):1036\u20131048.","DOI":"10.1111\/cbdd.12571"},{"issue":"22","key":"2472_CR142","doi-asserted-by":"publisher","first-page":"9265","DOI":"10.1158\/0008-5472.CAN-10-1530","volume":"70","author":"V Kapuria","year":"2010","unstructured":"Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 2010;70(22):9265\u201376.","journal-title":"Cancer Res"},{"issue":"5","key":"2472_CR143","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nchembio.2326","volume":"13","author":"J Li","year":"2017","unstructured":"Li J, Yakushi T, Parlati F, et al. Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. Nat Chem Biol. 2017;13(5):486\u201393.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2472_CR144","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41375-018-0167-0","volume":"33","author":"SH Barghout","year":"2019","unstructured":"Barghout SH, Patel PS, Wang X, et al. Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia. Leukemia. 2019;33(1):37\u201351.","journal-title":"Leukemia"},{"issue":"9","key":"2472_CR145","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-21-0344","volume":"28","author":"S Majeed","year":"2022","unstructured":"Majeed S, Aparnathi MK, Nixon KCJ, et al. Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small-cell lung cancer. Clin Cancer Res. 2022;28(9):1966\u201378.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2472_CR146","doi-asserted-by":"publisher","first-page":"9472","DOI":"10.1158\/0008-5472.CAN-07-0568","volume":"67","author":"Y Yang","year":"2007","unstructured":"Yang Y, Kitagaki J, Dai RM, et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 2007;67(19):9472\u201381.","journal-title":"Cancer Res"},{"issue":"22","key":"2472_CR147","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.1158\/0008-5472.CAN-18-1040","volume":"78","author":"A Dikshit","year":"2018","unstructured":"Dikshit A, Jin YJ, Degan S, et al. UBE2N promotes melanoma growth via MEK\/FRA1\/SOX10 signaling. Cancer Res. 2018;78(22):6462\u201372.","journal-title":"Cancer Res"},{"key":"2472_CR148","doi-asserted-by":"crossref","unstructured":"Ahmad I. Transition metal complexes as proteasome inhibitors for cancer treatment. Inorganica Chimica Acta. 2020;506.","DOI":"10.1016\/j.ica.2020.119521"},{"issue":"4","key":"2472_CR149","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1158\/0008-5472.CAN-06-3546","volume":"67","author":"D Chen","year":"2007","unstructured":"Chen D, Cui QC, Yang H, et al. Clioquinol, a therapeutic agent for Alzheimer\u2019s disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res. 2007;67(4):1636\u201344.","journal-title":"Cancer Res"},{"issue":"5","key":"2472_CR150","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/ja.2017.9","volume":"70","author":"I Momose","year":"2017","unstructured":"Momose I, Watanabe T. Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. J Antibiot (Tokyo). 2017;70(5):542\u201350.","journal-title":"J Antibiot (Tokyo)"},{"issue":"2","key":"2472_CR151","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.canlet.2015.06.011","volume":"366","author":"M Zang","year":"2015","unstructured":"Zang M, Li Z, Liu L, et al. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma. Cancer Lett. 2015;366(2):173\u201381.","journal-title":"Cancer Lett"},{"key":"2472_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2024.117221","volume":"495","author":"Z Li","year":"2025","unstructured":"Li Z, Nie J, Zhou R, et al. Thiostrepton suppresses colorectal cancer progression through reactive oxygen species related endoplasmic reticulum stress. Toxicol Appl Pharmacol. 2025;495:117221.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"2472_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-01657-0","volume":"15","author":"TW Jenkins","year":"2025","unstructured":"Jenkins TW, Fitzgerald JE, Park J, et al. Highly specific immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia. Sci Rep. 2025;15(1):17284.","journal-title":"Sci Rep"},{"issue":"19","key":"2472_CR154","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1182\/blood-2008-07-171637","volume":"113","author":"DJ Kuhn","year":"2009","unstructured":"Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 2009;113(19):4667\u201376.","journal-title":"Blood"},{"issue":"12","key":"2472_CR155","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1158\/1078-0432.CCR-13-2658","volume":"20","author":"K Coughlin","year":"2014","unstructured":"Coughlin K, Anchoori R, Iizuka Y, et al. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res. 2014;20(12):3174\u201386.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2472_CR156","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1021\/jm501336h","volume":"58","author":"U Cersosimo","year":"2015","unstructured":"Cersosimo U, Sgorbissa A, Foti C, et al. Synthesis, characterization, and optimization for in vivo delivery of a nonselective isopeptidase inhibitor as new antineoplastic agent. J Med Chem. 2015;58(4):1691\u2013704.","journal-title":"J Med Chem"},{"issue":"1","key":"2472_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01202-2","volume":"8","author":"L Iuliano","year":"2022","unstructured":"Iuliano L, Dalla E, Picco R, et al. Proteotoxic stress-induced apoptosis in cancer cells: understanding the susceptibility and enhancing the potency. Cell Death Discov. 2022;8(1):407.","journal-title":"Cell Death Discov"},{"key":"2472_CR158","doi-asserted-by":"crossref","unstructured":"Losada A, Berlanga JJ, Molina-Guijarro JM, et al. Generation of endoplasmic reticulum stress and inhibition of autophagy by plitidepsin induces proteotoxic apoptosis in cancer cells. Biochem Pharmacol. 2020;172.","DOI":"10.1016\/j.bcp.2019.113744"},{"issue":"3","key":"2472_CR159","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/1878-0261.13756","volume":"19","author":"E Phillips","year":"2025","unstructured":"Phillips E, van Enk S, Kildgaard S, et al. Malformin c preferentially kills glioblastoma stem-like cells via concerted induction of proteotoxic stress and autophagic flux blockade. Mol Oncol. 2025;19(3):785\u2013807.","journal-title":"Mol Oncol"},{"issue":"12","key":"2472_CR160","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.trecan.2020.07.006","volume":"6","author":"DP Raymundo","year":"2020","unstructured":"Raymundo DP, Doultsinos D, Guillory X, Carlesso A, Eriksson LA, Chevet E. Pharmacological targeting of IRE1 in cancer. Trends Cancer. 2020;6(12):1018\u201330.","journal-title":"Trends Cancer"},{"issue":"11","key":"2472_CR161","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/abbs\/gmab131","volume":"53","author":"M Yu","year":"2021","unstructured":"Yu M, Lun J, Zhang H, et al. Targeting UPR branches, a potential strategy for enhancing efficacy of cancer chemotherapy. Acta Biochim Biophys Sin. 2021;53(11):1417\u201327.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"2","key":"2472_CR162","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41573-021-00320-3","volume":"21","author":"SJ Marciniak","year":"2022","unstructured":"Marciniak SJ, Chambers JE, Ron D. Pharmacological targeting of endoplasmic reticulum stress in disease. Nat Rev Drug Discov. 2022;21(2):115\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"36","key":"2472_CR163","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.1038\/s41388-019-0890-7","volume":"38","author":"G Alasiri","year":"2019","unstructured":"Alasiri G, Jiramongkol Y, Zona S, et al. Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells. Oncogene. 2019;38(36):6382\u201398.","journal-title":"Oncogene"},{"issue":"11","key":"2472_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11113103","volume":"11","author":"ZZ Yu","year":"2023","unstructured":"Yu ZZ, Xu BQ, Wang YY, Zhang PW, Shu YB, Shi Z. GSK2606414 sensitizes ABCG2-overexpressing multidrug-resistant colorectal cancer cells to chemotherapeutic drugs. Biomedicines. 2023;11(11):3103.","journal-title":"Biomedicines"},{"key":"2472_CR165","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2021.05.021","volume":"515","author":"W Cai","year":"2021","unstructured":"Cai W, Sun X, Jin F, et al. PERK-eIF2\u03b1-ERK1\/2 axis drives mesenchymal-endothelial transition of cancer-associated fibroblasts in pancreatic cancer. Cancer Lett. 2021;515:86\u201395.","journal-title":"Cancer Lett"},{"issue":"10","key":"2472_CR166","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1021\/ml400228e","volume":"4","author":"JM Axten","year":"2013","unstructured":"Axten JM, Romeril SP, Shu A, et al. Discovery of GSK2656157: an optimized PERK inhibitor selected for preclinical development. ACS Med Chem Lett. 2013;4(10):964\u20138.","journal-title":"ACS Med Chem Lett"},{"issue":"6","key":"2472_CR167","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/cdd.2017.58","volume":"24","author":"D Rojas-Rivera","year":"2017","unstructured":"Rojas-Rivera D, Delvaeye T, Roelandt R, et al. When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157. Cell Death Differ. 2017;24(6):1100\u201310.","journal-title":"Cell Death Differ"},{"issue":"3","key":"2472_CR168","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1021\/jm5017494","volume":"58","author":"AL Smith","year":"2015","unstructured":"Smith AL, Andrews KL, Beckmann H, et al. Discovery of 1H-pyrazol-3(2h)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK). J Med Chem. 2015;58(3):1426\u201341.","journal-title":"J Med Chem"},{"key":"2472_CR169","doi-asserted-by":"crossref","unstructured":"Mohamed E, Sierra RA, Trillo-Tinoco J, et al. The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity. 2020;52(4):668\u2013682.e7.","DOI":"10.1016\/j.immuni.2020.03.004"},{"key":"2472_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.128058","volume":"43","author":"V Calvo","year":"2021","unstructured":"Calvo V, Surguladze D, Li AH, et al. Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors. Bioorg Med Chem Lett. 2021;43:128058.","journal-title":"Bioorg Med Chem Lett"},{"issue":"23","key":"2472_CR171","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1158\/1078-0432.CCR-23-1182","volume":"29","author":"ME Stokes","year":"2023","unstructured":"Stokes ME, Calvo V, Fujisawa S, et al. PERK inhibition by HC-5404 sensitizes renal cell carcinoma tumor models to antiangiogenic tyrosine kinase inhibitors. Clin Cancer Res. 2023;29(23):4870\u201382.","journal-title":"Clin Cancer Res"},{"key":"2472_CR172","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.11878","volume":"5","author":"CM Gallagher","year":"2016","unstructured":"Gallagher CM, Garri C, Cain EL, et al. Ceapins are a new class of unfolded protein response inhibitors, selectively targeting the ATF6\u03b1 branch. Elife. 2016;5:e11878.","journal-title":"Elife"},{"key":"2472_CR173","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.46595","volume":"8","author":"SE Torres","year":"2019","unstructured":"Torres SE, Gallagher CM, Plate L, et al. Ceapins block the unfolded protein response sensor ATF6\u03b1 by inducing a neomorphic inter-organelle tether. Elife. 2019;8:e46595.","journal-title":"Elife"},{"key":"2472_CR174","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.11880","volume":"5","author":"CM Gallagher","year":"2016","unstructured":"Gallagher CM, Walter P. Ceapins inhibit ATF6\u03b1 signaling by selectively preventing transport of ATF6\u03b1 to the Golgi apparatus during ER stress. Elife. 2016;5:e11880.","journal-title":"Elife"},{"issue":"5","key":"2472_CR175","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/pros.24308","volume":"82","author":"R Zhao","year":"2022","unstructured":"Zhao R, Lv Y, Feng T, et al. ATF6\u03b1 promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis. Prostate. 2022;82(5):617\u201329.","journal-title":"Prostate"},{"issue":"2","key":"2472_CR176","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201347R","volume":"37","author":"H Zhou","year":"2023","unstructured":"Zhou H, Zhang T, Chen L, et al. The functional implication of ATF6\u03b1 in castration-resistant prostate cancer cells. FASEB J. 2023;37(2):e22758.","journal-title":"FASEB J"},{"issue":"2","key":"2472_CR177","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2353\/ajpath.2007.070188","volume":"171","author":"WX Ding","year":"2007","unstructured":"Ding WX, Ni HM, Gao W, et al. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol. 2007;171(2):513\u201324.","journal-title":"Am J Pathol"},{"issue":"14","key":"2472_CR178","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143379","volume":"20","author":"N Albornoz","year":"2019","unstructured":"Albornoz N, Bustamante H, Soza A, Burgos P. Cellular responses to proteasome inhibition: molecular mechanisms and beyond. Int J Mol Sci. 2019;20(14):3379.","journal-title":"Int J Mol Sci"},{"issue":"26","key":"2472_CR179","doi-asserted-by":"publisher","first-page":"17067","DOI":"10.1016\/S0021-9258(19)47340-7","volume":"266","author":"J Lytton","year":"1991","unstructured":"Lytton J, Westlin M, Hanley MR. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem. 1991;266(26):17067\u201371.","journal-title":"J Biol Chem"},{"issue":"Pt 3","key":"2472_CR180","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1042\/bj20020279","volume":"366","author":"AJ Johnson","year":"2002","unstructured":"Johnson AJ, Hsu AL, Lin HP, Song X, Chen CS. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J. 2002;366(Pt 3):831\u20137.","journal-title":"Biochem J"},{"issue":"9\u201310","key":"2472_CR181","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1089\/ars.2006.8.1391","volume":"8","author":"A G\u00f6rlach","year":"2006","unstructured":"G\u00f6rlach A, Klappa P, Kietzmann T. The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. Antioxid Redox Signal. 2006;8(9\u201310):1391\u2013418.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"2472_CR182","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0935-8","volume":"37","author":"J Wu","year":"2018","unstructured":"Wu J, Chen S, Liu H, et al. Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation. J Exp Clin Cancer Res. 2018;37(1):272.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"2472_CR183","first-page":"541","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang L, He Z, et al. Tunicamycin induces ER stress and inhibits tumorigenesis of head and neck cancer cells by inhibiting N-glycosylation. Am J Transl Res. 2020;12(2):541\u201350.","journal-title":"Am J Transl Res."},{"key":"2472_CR184","doi-asserted-by":"crossref","unstructured":"Wang J, Chen M, Wang M, et al. The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAP via ER stress in pancreatic cancer cells [published correction appears in Acta Pharm Sin B. 2025;15(2):1208\u20131209. doi: 10.1016\/j.apsb.2024.10.013.]. Acta Pharm Sin B. 2022;12(1):210\u2013227.","DOI":"10.1016\/j.apsb.2021.07.004"},{"issue":"16","key":"2472_CR185","doi-asserted-by":"publisher","first-page":"7193","DOI":"10.1021\/jm300713s","volume":"55","author":"JM Axten","year":"2012","unstructured":"Axten JM, Medina JR, Feng Y, et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem. 2012;55(16):7193\u2013207.","journal-title":"J Med Chem"},{"key":"2472_CR186","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.steroids.2014.07.009","volume":"97","author":"NT Doan","year":"2015","unstructured":"Doan NT, Paulsen ES, Sehgal P, et al. Targeting thapsigargin towards tumors. Steroids. 2015;97:2\u20137.","journal-title":"Steroids"},{"issue":"40","key":"2472_CR187","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022544","volume":"99","author":"B Wen","year":"2020","unstructured":"Wen B, Wei YT, Mu LL, Wen GR, Zhao K. The molecular mechanisms of celecoxib in tumor development. Medicine (Baltimore). 2020;99(40):e22544.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"2472_CR188","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015479","volume":"5","author":"Q Wang","year":"2010","unstructured":"Wang Q, Shinkre BA, Lee JG, et al. The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97\/VCP inhibitory group. PLoS One. 2010;5(11):e15479.","journal-title":"PLoS One"},{"issue":"1","key":"2472_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06434-x","volume":"15","author":"DM Lee","year":"2024","unstructured":"Lee DM, Kim IY, Lee HJ, et al. Akt enhances the vulnerability of cancer cells to VCP\/p97 inhibition-mediated paraptosis. Cell Death Dis. 2024;15(1):48.","journal-title":"Cell Death Dis"},{"key":"2472_CR190","doi-asserted-by":"crossref","unstructured":"Magnaghi P, D\u2019Alessio R, Valsasina B, et al. Covalent and allosteric inhibitors of the ATPase VCP\/p97 induce cancer cell death. Nat Chem Biol. 2013;9(9):548\u2013556.","DOI":"10.1038\/nchembio.1313"},{"key":"2472_CR191","unstructured":"Zhao Z, Wu M, Zhang X, et al. CB-5083, an inhibitor of P97, suppresses osteosarcoma growth and stem cell properties by altering protein homeostasis. Am J Transl Res. 2020;12(6):2956\u20132967."},{"issue":"5","key":"2472_CR192","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ccell.2015.10.002","volume":"28","author":"DJ Anderson","year":"2015","unstructured":"Anderson DJ, Le Moigne R, Djakovic S, et al. Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis. Cancer Cell. 2015;28(5):653\u201365.","journal-title":"Cancer Cell"},{"issue":"13","key":"2472_CR193","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1080\/15384101.2020.1754584","volume":"19","author":"NG Her","year":"2020","unstructured":"Her NG, Kesari S, Nurmemmedov E. Thrombospondin-1 counteracts the p97 inhibitor CB-5083 in colon carcinoma cells. Cell Cycle. 2020;19(13):1590\u2013601.","journal-title":"Cell Cycle"},{"issue":"1","key":"2472_CR194","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.chembiol.2022.12.007","volume":"30","author":"S Kilgas","year":"2023","unstructured":"Kilgas S, Ramadan K. Inhibitors of the ATPase p97\/VCP: from basic research to clinical applications. Cell Chem Biol. 2023;30(1):3\u201321.","journal-title":"Cell Chem Biol"},{"issue":"587","key":"2472_CR195","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg1168","volume":"13","author":"B Roux","year":"2021","unstructured":"Roux B, Vaganay C, Vargas JD, et al. Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Sci Transl Med. 2021;13(587):eabg1168.","journal-title":"Sci Transl Med"},{"issue":"12","key":"2472_CR196","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1073\/pnas.1015312108","volume":"108","author":"TF Chou","year":"2011","unstructured":"Chou TF, Brown SJ, Minond D, et al. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci U S A. 2011;108(12):4834\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2472_CR197","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.trecan.2023.08.005","volume":"9","author":"A Redding","year":"2023","unstructured":"Redding A, Grabocka E. Stress granules and hormetic adaptation of cancer. Trends Cancer. 2023;9(12):995\u20131005.","journal-title":"Trends Cancer"},{"issue":"9","key":"2472_CR198","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.tcb.2016.05.004","volume":"26","author":"DSW Protter","year":"2016","unstructured":"Protter DSW, Parker R. Principles and properties of stress granules. Trends Cell Biol. 2016;26(9):668\u201379.","journal-title":"Trends Cell Biol"},{"issue":"3","key":"2472_CR199","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1074\/jbc.M110.179440","volume":"286","author":"YJ Yoon","year":"2011","unstructured":"Yoon YJ, Kim JA, Shin KD, et al. KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter. J Biol Chem. 2011;286(3):1737\u201347.","journal-title":"J Biol Chem"},{"issue":"8","key":"2472_CR200","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/09553000412331283470","volume":"80","author":"K Ohnishi","year":"2004","unstructured":"Ohnishi K, Takahashi A, Yokota S, Ohnishi T. Effects of a heat shock protein inhibitor KNK437 on heat sensitivity and heat tolerance in human squamous cell carcinoma cell lines differing in p53 status. Int J Radiat Biol. 2004;80(8):607\u201314.","journal-title":"Int J Radiat Biol"},{"issue":"3","key":"2472_CR201","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00280-009-1194-3","volume":"66","author":"AJ Massey","year":"2010","unstructured":"Massey AJ, Williamson DS, Browne H, et al. A novel, small molecule inhibitor of Hsc70\/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol. 2010;66(3):535\u201345.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2472_CR202","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/1535370214527899","volume":"239","author":"W Wen","year":"2014","unstructured":"Wen W, Liu W, Shao Y, Chen L. VER-155008, a small molecule inhibitor of HSP70 with potent anti-cancer activity on lung cancer cell lines. Exp Biol Med (Maywood). 2014;239(5):638\u201345.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"2472_CR203","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1535-7163.MCT-18-0432","volume":"18","author":"J Dong","year":"2019","unstructured":"Dong J, Wu Z, Wang D, et al. Hsp70 binds to the androgen receptor N-terminal domain and modulates the receptor function in prostate cancer cells. Mol Cancer Ther. 2019;18(1):39\u201350.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2472_CR204","first-page":"2585","volume":"12","author":"F Xu","year":"2019","unstructured":"Xu F, Lin D, Jiang W, et al. HSP70 inhibitor VER155008 suppresses pheochromocytoma cell and xenograft growth by inhibition of PI3K\/AKT\/mTOR and MEK\/ERK pathways. Int J Clin Exp Pathol. 2019;12(7):2585\u201394.","journal-title":"Int J Clin Exp Pathol."},{"issue":"49","key":"2472_CR205","doi-asserted-by":"publisher","first-page":"51131","DOI":"10.1074\/jbc.M404857200","volume":"279","author":"SW Fewell","year":"2004","unstructured":"Fewell SW, Smith CM, Lyon MA, et al. Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity. J Biol Chem. 2004;279(49):51131\u201340.","journal-title":"J Biol Chem"},{"issue":"2","key":"2472_CR206","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/embor.2010.203","volume":"12","author":"M Gamerdinger","year":"2011","unstructured":"Gamerdinger M, Kaya AM, Wolfrum U, Clement AM, Behl C. BAG3 mediates chaperone-based aggresome-targeting and selective autophagy of misfolded proteins. EMBO Rep. 2011;12(2):149\u201356.","journal-title":"EMBO Rep"},{"issue":"3","key":"2472_CR207","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1158\/1535-7163.MCT-14-0650","volume":"14","author":"X Li","year":"2015","unstructured":"Li X, Colvin T, Rauch JN, et al. Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer. Mol Cancer Ther. 2015;14(3):642\u20138.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2472_CR208","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrm.2017.20","volume":"18","author":"FH Schopf","year":"2017","unstructured":"Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 2017;18(6):345\u201360.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2472_CR209","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.canlet.2009.07.010","volume":"290","author":"Y Fukuyo","year":"2010","unstructured":"Fukuyo Y, Hunt CR, Horikoshi N. Geldanamycin and its anti-cancer activities. Cancer Lett. 2010;290(1):24\u201335.","journal-title":"Cancer Lett"},{"issue":"1","key":"2472_CR210","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3816\/CLML.2011.n.002","volume":"11","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG. Tanespimycin as antitumor therapy. Clin Lymphoma Myeloma Leuk. 2011;11(1):17\u201322.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2472_CR211","doi-asserted-by":"publisher","first-page":"2","DOI":"10.59786\/bmtj.122","volume":"1","author":"AM Alzebari","year":"2023","unstructured":"Alzebari AM, Qadir AM, Rafaat MS, Salihi A. Therapeutic potential of heat shock protein 90 inhibitors, geldanamycin, and analog compounds in precision cancer therapy. BioMed Target Journal. 2023;1(2):2\u201321.","journal-title":"BioMed Target Journal"},{"issue":"1","key":"2472_CR212","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3892\/or.2022.8443","volume":"49","author":"ZN Li","year":"2023","unstructured":"Li ZN, Luo Y. HSP90 inhibitors and cancer: prospects for use in targeted therapies (review). Oncol Rep. 2023;49(1):6.","journal-title":"Oncol Rep"},{"issue":"8","key":"2472_CR213","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1158\/0008-5472.CAN-07-5256","volume":"68","author":"SA Eccles","year":"2008","unstructured":"Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008;68(8):2850\u201360.","journal-title":"Cancer Res"},{"issue":"26","key":"2472_CR214","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.2174\/092986708786242895","volume":"15","author":"A Donnelly","year":"2008","unstructured":"Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem. 2008;15(26):2702\u201317.","journal-title":"Curr Med Chem"},{"issue":"11","key":"2472_CR215","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1074\/jbc.M512406200","volume":"281","author":"RK Allan","year":"2006","unstructured":"Allan RK, Mok D, Ward BK, Ratajczak T. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. J Biol Chem. 2006;281(11):7161\u201371.","journal-title":"J Biol Chem"},{"key":"2472_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114218","volume":"182","author":"J Dai","year":"2020","unstructured":"Dai J, Zhu M, Qi X, et al. Fungal mycotoxin penisuloxazin A, a novel C-terminal Hsp90 inhibitor and characteristics of its analogues on Hsp90 function related to binding sites. Biochem Pharmacol. 2020;182:114218.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"2472_CR217","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.62347\/XFJH3424","volume":"14","author":"GH Li","year":"2024","unstructured":"Li GH, Miao Y, Chen H, et al. The small-molecule drug homoharringtonine targets HSF1 to suppress pancreatic cancer progression. Am J Cancer Res. 2024;14(5):2072\u201387.","journal-title":"Am J Cancer Res."},{"issue":"7","key":"2472_CR218","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069509","volume":"8","author":"W Qi","year":"2013","unstructured":"Qi W, White MC, Choi W, et al. Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. PLoS One. 2013;8(7):e69509.","journal-title":"PLoS One"},{"issue":"23","key":"2472_CR219","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.4161\/cc.8.23.10179","volume":"8","author":"N Neznanov","year":"2009","unstructured":"Neznanov N, Gorbachev AV, Neznanova L, et al. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle. 2009;8(23):3960\u201370.","journal-title":"Cell Cycle"},{"issue":"17","key":"2472_CR220","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27175561","volume":"27","author":"X Pan","year":"2022","unstructured":"Pan X, Mao TY, Mai YW, et al. Discovery of quinacrine as a potent Topo II and Hsp90 dual-target inhibitor, repurposing for cancer therapy. Molecules. 2022;27(17):5561.","journal-title":"Molecules"},{"key":"2472_CR221","doi-asserted-by":"crossref","unstructured":"Li N, Wang T, Li Z, et al. Dorsomorphin induces cancer cell apoptosis and sensitizes cancer cells to HSP90 and proteasome inhibitors by reducing nuclear heat shock factor 1 levels. Cancer Biol Med. 2019;16(2):220\u2013233.","DOI":"10.20892\/j.issn.2095-3941.2018.0235"},{"issue":"6143","key":"2472_CR222","doi-asserted-by":"publisher","DOI":"10.1126\/science.1238303","volume":"341","author":"S Santagata","year":"2013","unstructured":"Santagata S, Mendillo ML, Tang YC, et al. Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science. 2013;341(6143):1238303.","journal-title":"Science"},{"issue":"1","key":"2472_CR223","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.canlet.2013.07.023","volume":"339","author":"L Zhang","year":"2013","unstructured":"Zhang L, Fok JJ, Mirabella F, et al. Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress. Cancer Lett. 2013;339(1):49\u201359.","journal-title":"Cancer Lett"},{"issue":"4","key":"2472_CR224","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092041","volume":"9","author":"C Adam","year":"2014","unstructured":"Adam C, Baeurle A, Brodsky JL, et al. The HSP70 modulator MAL3-101 inhibits Merkel cell carcinoma. PLoS One. 2014;9(4):e92041.","journal-title":"PLoS One"},{"issue":"1","key":"2472_CR225","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14900-0","volume":"8","author":"JA Yaglom","year":"2018","unstructured":"Yaglom JA, Wang Y, Li A, et al. Cancer cell responses to Hsp70 inhibitor JG-98: comparison with Hsp90 inhibitors and finding synergistic drug combinations. Sci Rep. 2018;8(1):3010.","journal-title":"Sci Rep"},{"issue":"46","key":"2472_CR226","doi-asserted-by":"publisher","first-page":"17408","DOI":"10.1073\/pnas.0608372103","volume":"103","author":"JR Sydor","year":"2006","unstructured":"Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A. 2006;103(46):17408\u201313.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2472_CR227","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00280-007-0546-0","volume":"61","author":"J Patterson","year":"2008","unstructured":"Patterson J, Palombella VJ, Fritz C, Normant E. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol. 2008;61(6):923\u201332.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2472_CR228","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/1535-7163.MCT-08-0758","volume":"8","author":"K Lundgren","year":"2009","unstructured":"Lundgren K, Zhang H, Brekken J, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009;8(4):921\u20139.","journal-title":"Mol Cancer Ther"},{"key":"2472_CR229","doi-asserted-by":"crossref","unstructured":"Zhang J, Liu L, Li Y, et al. HSP90 C-terminal domain inhibition promotes VDAC1 oligomerization via decreasing K274 mono-ubiquitination in Hepatocellular Carcinoma. Neoplasia. 2023;44:100935.","DOI":"10.1016\/j.neo.2023.100935"},{"key":"2472_CR230","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00974","volume":"11","author":"H Chen","year":"2020","unstructured":"Chen H, Gong Y, Ma Y, et al. A brain-penetrating Hsp90 inhibitor NXD30001 inhibits glioblastoma as a monotherapy or in combination with radiation. Front Pharmacol. 2020;11:974.","journal-title":"Front Pharmacol"},{"issue":"13","key":"2472_CR231","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137459","volume":"25","author":"AMIA Hassan","year":"2024","unstructured":"Hassan AMIA, Zhao Y, Chen X, He C. Blockage of autophagy for cancer therapy: a comprehensive review. Int J Mol Sci. 2024;25(13):7459.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2472_CR232","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01713-z","volume":"25","author":"J Sedlacek","year":"2025","unstructured":"Sedlacek J. Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma. Clin Exp Med. 2025;25(1):176.","journal-title":"Clin Exp Med"},{"issue":"9","key":"2472_CR233","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1158\/1541-7786.MCR-06-0019","volume":"4","author":"EG Mimnaugh","year":"2006","unstructured":"Mimnaugh EG, Xu W, Vos M, Yuan X, Neckers L. Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade. Mol Cancer Res. 2006;4(9):667\u201381.","journal-title":"Mol Cancer Res"},{"key":"2472_CR234","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-233","volume":"12","author":"M Peron","year":"2012","unstructured":"Peron M, Bonvini P, Rosolen A. Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro. BMC Cancer. 2012;12:233.","journal-title":"BMC Cancer"},{"issue":"22","key":"2472_CR235","doi-asserted-by":"publisher","first-page":"5560","DOI":"10.1002\/cncr.27586","volume":"118","author":"B Hui","year":"2012","unstructured":"Hui B, Shi YH, Ding ZB, et al. Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma. Cancer. 2012;118(22):5560\u201371.","journal-title":"Cancer"},{"issue":"8","key":"2472_CR236","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.4161\/auto.29264","volume":"10","author":"DT Vogl","year":"2014","unstructured":"Vogl DT, Stadtmauer EA, Tan KS, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed\/refractory myeloma. Autophagy. 2014;10(8):1380\u201390.","journal-title":"Autophagy"},{"issue":"23","key":"2472_CR237","doi-asserted-by":"publisher","first-page":"34988","DOI":"10.18632\/oncotarget.9222","volume":"7","author":"YP Van dewynckel","year":"2016","unstructured":"Van dewynckel YP, Coucke C, Laukens D, et al. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma. Oncotarget. 2016;7(23):34988\u20135000.","journal-title":"Oncotarget"},{"issue":"16","key":"2472_CR238","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1111\/jcmm.17479","volume":"26","author":"S Creedican","year":"2022","unstructured":"Creedican S, Robinson CM, Mnich K, et al. Inhibition of IRE1\u03b1 RNase activity sensitizes patient-derived acute myeloid leukaemia cells to proteasome inhibitors. J Cell Mol Med. 2022;26(16):4629\u201333.","journal-title":"J Cell Mol Med"},{"key":"2472_CR239","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.leukres.2016.07.006","volume":"49","author":"L Chen","year":"2016","unstructured":"Chen L, Li Q, She T, et al. IRE1\u03b1-XBP1 signaling pathway, a potential therapeutic target in multiple myeloma. Leuk Res. 2016;49:7\u201312.","journal-title":"Leuk Res"},{"issue":"7","key":"2472_CR240","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/15548627.2015.1052928","volume":"11","author":"E Milan","year":"2015","unstructured":"Milan E, Perini T, Resnati M, et al. A plastic SQSTM1\/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells. Autophagy. 2015;11(7):1161\u201378.","journal-title":"Autophagy"},{"issue":"3","key":"2472_CR241","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/onc.2009.343","volume":"29","author":"K Zhu","year":"2010","unstructured":"Zhu K, Dunner K Jr., McConkey DJ. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene. 2010;29(3):451\u201362.","journal-title":"Oncogene"},{"issue":"2","key":"2472_CR242","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.bbrc.2008.07.031","volume":"374","author":"WK Wu","year":"2008","unstructured":"Wu WK, Wu YC, Yu L, Li ZJ, Sung JJ, Cho CH. Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells. Biochem Biophys Res Commun. 2008;374(2):258\u201363.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"2472_CR243","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1177\/0300060513490618","volume":"41","author":"Z Lou","year":"2013","unstructured":"Lou Z, Ren T, Peng X, et al. Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro. J Int Med Res. 2013;41(5):1505\u201319.","journal-title":"J Int Med Res"},{"issue":"5","key":"2472_CR244","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1083\/jcb.201708168","volume":"217","author":"Z Sha","year":"2018","unstructured":"Sha Z, Schnell HM, Ruoff K, Goldberg A. Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation. J Cell Biol. 2018;217(5):1757\u201376.","journal-title":"J Cell Biol"},{"issue":"7","key":"2472_CR245","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05061-8","volume":"13","author":"C Zhang","year":"2022","unstructured":"Zhang C, Huang C, Xia H, Xu H, Tang Q, Bi F. Autophagic sequestration of SQSTM1 disrupts the aggresome formation of ubiquitinated proteins during proteasome inhibition. Cell Death Dis. 2022;13(7):615.","journal-title":"Cell Death Dis"},{"issue":"21","key":"2472_CR246","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202105469","volume":"9","author":"R Xiao","year":"2022","unstructured":"Xiao R, You L, Zhang L, et al. Inhibiting the IRE1\u03b1 axis of the unfolded protein response enhances the antitumor effect of AZD1775 in TP53 mutant ovarian cancer. Adv Sci. 2022;9(21):e2105469.","journal-title":"Adv Sci"},{"key":"2472_CR247","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-017-0002-9","author":"A Storniolo","year":"2018","unstructured":"Storniolo A, Alfano V, Carbotta S, Ferretti E, Di Renzo L. IRE1\u03b1 deficiency promotes tumor cell death and eIF2\u03b1 degradation through PERK dipendent autophagy. Cell Death Discov. 2018. https:\/\/doi.org\/10.1038\/s41420-017-0002-9.","journal-title":"Cell Death Discov"},{"key":"2472_CR248","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.apsusc.2019.05.099","volume":"487","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan A, Kaushik M, Niranjan R, Richards JS, Ebright B, Venkatasubbu GD. Zinc oxide nanoparticles induce oxidative and proteotoxic stress in ovarian cancer cells and trigger apoptosis independent of p53-mutation status. Appl Surf Sci. 2019;487:807\u201318.","journal-title":"Appl Surf Sci"},{"issue":"16","key":"2472_CR249","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164217","volume":"13","author":"CM Snyder","year":"2021","unstructured":"Snyder CM, Rohde MM, Fahrenholtz CD, et al. Low doses of silver nanoparticles selectively induce lipid peroxidation and proteotoxic stress in mesenchymal subtypes of triple-negative breast cancer. Cancers (Basel). 2021;13(16):4217.","journal-title":"Cancers (Basel)"},{"key":"2472_CR250","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1007\/s12274-021-3312-4","volume":"14","author":"J Wang","year":"2021","unstructured":"Wang J, Huang M, Chen S, et al. Nanomedicine-mediated ubiquitination inhibition boosts antitumor immune response via activation of dendritic cells. Nano Res. 2021;14:3900\u20136.","journal-title":"Nano Res"},{"issue":"1","key":"2472_CR251","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00955-y","volume":"13","author":"D Dutta","year":"2023","unstructured":"Dutta D, Liu J, Wen K, et al. BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma. Blood Cancer J. 2023;13(1):184.","journal-title":"Blood Cancer J"},{"issue":"9","key":"2472_CR252","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092709","volume":"12","author":"A Nigro","year":"2020","unstructured":"Nigro A, Frattaruolo L, Fava M, et al. Bortezomib-loaded mesoporous silica nanoparticles selectively alter metabolism and induce death in multiple myeloma cells. Cancers (Basel). 2020;12(9):2709.","journal-title":"Cancers (Basel)"},{"issue":"48","key":"2472_CR253","doi-asserted-by":"publisher","first-page":"41003","DOI":"10.1021\/acsami.8b07527","volume":"10","author":"M Wang","year":"2018","unstructured":"Wang M, Cai X, Yang J, et al. A targeted and ph-responsive bortezomib nanomedicine in the treatment of metastatic bone tumors. ACS Appl Mater Interfaces. 2018;10(48):41003\u201311.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"21","key":"2472_CR254","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1158\/0008-5472.CAN-18-3029","volume":"79","author":"MH Chui","year":"2019","unstructured":"Chui MH, Doodnauth SA, Erdmann N, et al. Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma. Cancer Res. 2019;79(21):5536\u201349.","journal-title":"Cancer Res"},{"issue":"1","key":"2472_CR255","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"issue":"4","key":"2472_CR256","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.21873\/invivo.12917","volume":"36","author":"YJ Lee","year":"2022","unstructured":"Lee YJ, Seol A, Lee M, et al. A phase II trial to evaluate the efficacy of Bortezomib and Liposomal Doxorubicin in patients with BRCA wild-type platinum-resistant recurrent ovarian cancer (KGOG 3044\/EBLIN). In Vivo. 2022;36(4):1949\u201358.","journal-title":"In Vivo"},{"issue":"562","key":"2472_CR257","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay0152","volume":"12","author":"TY Jiang","year":"2020","unstructured":"Jiang TY, Pan YF, Wan ZH, et al. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma. Sci Transl Med. 2020;12(562):eaay0152.","journal-title":"Sci Transl Med"},{"key":"2472_CR258","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.canlet.2020.11.016","volume":"501","author":"TY Jiang","year":"2021","unstructured":"Jiang TY, Feng XF, Fang Z, et al. Pten deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer. Cancer Lett. 2021;501:187\u201399.","journal-title":"Cancer Lett"},{"issue":"7","key":"2472_CR259","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/neuonc\/noab001","volume":"23","author":"JA Benitez","year":"2021","unstructured":"Benitez JA, Finlay D, Castanza A, et al. PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma. Neuro Oncol. 2021;23(7):1072\u201386.","journal-title":"Neuro Oncol"},{"issue":"22","key":"2472_CR260","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1038\/s41388-019-0717-6","volume":"38","author":"M Wang","year":"2019","unstructured":"Wang M, Ferreira RB, Law ME, et al. A novel proteotoxic combination therapy for EGFR\u2009+\u2009and HER2\u2009+\u2009cancers. Oncogene. 2019;38(22):4264\u201382.","journal-title":"Oncogene"},{"issue":"378","key":"2472_CR261","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaa6922","volume":"8","author":"N Singh","year":"2015","unstructured":"Singh N, Joshi R, Komurov K. HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive. Sci Signal. 2015;8(378):ra52.","journal-title":"Sci Signal"},{"issue":"4","key":"2472_CR262","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc2819","volume":"10","author":"J Riggelen","year":"2010","unstructured":"Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010;10(4):301\u20139.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2472_CR263","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1172\/JCI95873","volume":"128","author":"N Zhao","year":"2018","unstructured":"Zhao N, Cao J, Xu L, et al. Pharmacological targeting of MYC-regulated IRE1\/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest. 2018;128(4):1283\u201399.","journal-title":"J Clin Invest"},{"issue":"11","key":"2472_CR264","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027988","volume":"6","author":"A Frenzel","year":"2011","unstructured":"Frenzel A, Zirath H, Vita M, Albihn A, Henriksson MA. Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression. PLoS One. 2011;6(11):e27988.","journal-title":"PLoS One"},{"issue":"7","key":"2472_CR265","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/s41556-019-0347-9","volume":"21","author":"F Tameire","year":"2019","unstructured":"Tameire F, Verginadis II, Leli NM, et al. Atf4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression. Nat Cell Biol. 2019;21(7):889\u201399.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"2472_CR266","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41417-021-00326-4","volume":"29","author":"T Suzuki","year":"2022","unstructured":"Suzuki T, Kishikawa T, Sato T, et al. Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells. Cancer Gene Ther. 2022;29(5):505\u201318.","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"2472_CR267","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a003665","volume":"5","author":"A Drilon","year":"2019","unstructured":"Drilon A, Schoenfeld AJ, Arbour KC, et al. Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Cold Spring Harb Mol Case Stud. 2019;5(2):a003665.","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"11","key":"2472_CR268","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/sj.onc.1203462","volume":"19","author":"S Ren","year":"2000","unstructured":"Ren S, Smith MJ, Louro ID, et al. The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma. Oncogene. 2000;19(11):1419\u201327.","journal-title":"Oncogene"},{"issue":"4","key":"2472_CR269","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s10571-022-01261-0","volume":"43","author":"J Vriend","year":"2023","unstructured":"Vriend J, Klonisch T. Genes of the ubiquitin proteasome system qualify as differential markers in malignant glioma of astrocytic and oligodendroglial origin. Cell Mol Neurobiol. 2023;43(4):1425\u201352.","journal-title":"Cell Mol Neurobiol"},{"issue":"3","key":"2472_CR270","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/cncr.23224","volume":"112","author":"A Busse","year":"2008","unstructured":"Busse A, Kraus M, Na IK, et al. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer. 2008;112(3):659\u201370.","journal-title":"Cancer"},{"issue":"6","key":"2472_CR271","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2174\/1568009617666171002144228","volume":"18","author":"S Sajadimajd","year":"2018","unstructured":"Sajadimajd S, Khazaei M. Oxidative stress and cancer: the role of Nrf2. Curr Cancer Drug Targets. 2018;18(6):538\u201357.","journal-title":"Curr Cancer Drug Targets"},{"issue":"33","key":"2472_CR272","doi-asserted-by":"publisher","first-page":"20004","DOI":"10.1073\/pnas.2005052117","volume":"117","author":"F Shirazi","year":"2020","unstructured":"Shirazi F, Jones RJ, Singh RK, et al. Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma. Proc Natl Acad Sci U S A. 2020;117(33):20004\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2472_CR273","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-02569-9","volume":"15","author":"K Sung","year":"2025","unstructured":"Sung K, Hosoya K, Deguchi T, et al. Glutathione-associated redox regulation alleviates radio-resistance of canine cancer stem-like cells with low proteasome activity. Sci Rep. 2025;15(1):18017.","journal-title":"Sci Rep"},{"issue":"4","key":"2472_CR274","doi-asserted-by":"publisher","first-page":"e1194","DOI":"10.1038\/cddis.2014.158","volume":"5","author":"D Li","year":"2014","unstructured":"Li D, Yallowitz A, Ozog L, Marchenko N. A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress. Cell Death Dis. 2014;5(4):e1194.","journal-title":"Cell Death Dis"},{"issue":"10","key":"2472_CR275","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/2767-9764.CRC-23-0637","volume":"4","author":"KK Chougoni","year":"2024","unstructured":"Chougoni KK, Neely V, Ding B, et al. Oncogenic mutant p53 sensitizes non-small cell lung cancer cells to proteasome inhibition via oxidative stress-dependent induction of mitochondrial apoptosis. Cancer Res Commun. 2024;4(10):2685\u201398.","journal-title":"Cancer Res Commun"},{"issue":"8","key":"2472_CR276","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ncb3380","volume":"18","author":"D Walerych","year":"2016","unstructured":"Walerych D, Lisek K, Sommaggio R, et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol. 2016;18(8):897\u2013909.","journal-title":"Nat Cell Biol"},{"issue":"52","key":"2472_CR277","doi-asserted-by":"publisher","first-page":"E8433","DOI":"10.1073\/pnas.1612711114","volume":"113","author":"F Vogiatzi","year":"2016","unstructured":"Vogiatzi F, Brandt DT, Schneikert J, et al. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. Proc Natl Acad Sci U S A. 2016;113(52):E8433\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2472_CR278","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24064-1","volume":"12","author":"T Isermann","year":"2021","unstructured":"Isermann T, \u015eener \u00d6\u00c7, Stender A, et al. Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity. Nat Commun. 2021;12(1):4019.","journal-title":"Nat Commun"},{"key":"2472_CR279","doi-asserted-by":"publisher","unstructured":"Isermann T, Schneider KL, Wegwitz F, et al. Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition. Cell Death Differ. Published online April 9, 2025. https:\/\/doi.org\/10.1038\/s41418-025-01502-x.","DOI":"10.1038\/s41418-025-01502-x."},{"issue":"9","key":"2472_CR280","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075280","volume":"8","author":"S Manni","year":"2013","unstructured":"Manni S, Brancalion A, Mandato E, et al. Protein kinase CK2 inhibition down modulates the NF-\u03baB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. PLoS One. 2013;8(9):e75280.","journal-title":"PLoS One"},{"issue":"2","key":"2472_CR281","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1158\/0008-5472.CAN-19-3922","volume":"81","author":"H Tomihara","year":"2021","unstructured":"Tomihara H, Carbone F, Perelli L, et al. Loss of ARID1A promotes epithelial-mesenchymal transition and sensitizes pancreatic tumors to proteotoxic stress. Cancer Res. 2021;81(2):332\u201343.","journal-title":"Cancer Res"},{"issue":"11","key":"2472_CR282","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1158\/0008-5472.CAN-20-2694","volume":"81","author":"Y Murai","year":"2021","unstructured":"Murai Y, Jo U, Murai J, et al. SLFN11 inactivation induces proteotoxic stress and sensitizes cancer cells to ubiquitin activating enzyme inhibitor TAK-243. Cancer Res. 2021;81(11):3067\u201378.","journal-title":"Cancer Res"},{"issue":"5","key":"2472_CR283","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41418-020-00686-8","volume":"28","author":"R Moreno","year":"2021","unstructured":"Moreno R, Banerjee S, Jackson AW, et al. The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress. Cell Death Differ. 2021;28(5):1563\u201378.","journal-title":"Cell Death Differ"},{"issue":"17","key":"2472_CR284","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1038\/s41388-018-0651-z","volume":"38","author":"K Parzych","year":"2019","unstructured":"Parzych K, Saavedra-Garc\u00eda P, Valbuena GN, et al. The coordinated action of VCP\/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation. Oncogene. 2019;38(17):3216\u201331.","journal-title":"Oncogene"},{"issue":"1\u20132","key":"2472_CR285","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10495-022-01779-0","volume":"28","author":"J Adamczyk-Grochala","year":"2023","unstructured":"Adamczyk-Grochala J, Bloniarz D, Zielinska K, Lewinska A, Wnuk M. DNMT2\/TRDMT1 gene knockout compromises doxorubicin-induced unfolded protein response and sensitizes cancer cells to ER stress-induced apoptosis. Apoptosis. 2023;28(1\u20132):166\u201385.","journal-title":"Apoptosis"},{"issue":"11","key":"2472_CR286","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107877","volume":"300","author":"Q Zeidan","year":"2024","unstructured":"Zeidan Q, Tian JL, Ma J, Eslami F, Hart GW. O-GlcNAcylation of ribosome-associated proteins is concomitant with translational reprogramming during proteotoxic stress. J Biol Chem. 2024;300(11):107877.","journal-title":"J Biol Chem"},{"key":"2472_CR287","doi-asserted-by":"crossref","unstructured":"Marino S, Petrusca DN, Bishop RT, et al. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma. Haematologica. 2024;109(5):1501\u20131513.","DOI":"10.3324\/haematol.2023.283787"},{"issue":"10","key":"2472_CR288","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.3390\/cancers13102341","volume":"13","author":"\u00d6 \u00d6.","year":"2021","unstructured":"\u00d6. \u00d6, \u00d6rd D, Kaikkonen MU, \u00d6rd T. Pharmacological or TRIB3-mediated suppression of ATF4 transcriptional activity promotes hepatoma cell resistance to proteasome inhibitor bortezomib. Cancers (Basel). 2021;13(10):2341.","journal-title":"Cancers (Basel)"},{"issue":"14","key":"2472_CR289","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146893","volume":"131","author":"C Li","year":"2021","unstructured":"Li C, Xia J, Franqui-Machin R, et al. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. J Clin Invest. 2021;131(14):e146893.","journal-title":"J Clin Invest"},{"issue":"1","key":"2472_CR290","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-023-00500-6","volume":"28","author":"C Zhang","year":"2023","unstructured":"Zhang C, Duan Y, Huang C, Li L. Inhibition of SQSTM1 S403 phosphorylation facilitates the aggresome formation of ubiquitinated proteins during proteasome dysfunction. Cell Mol Biol Lett. 2023;28(1):85.","journal-title":"Cell Mol Biol Lett"},{"issue":"14","key":"2472_CR291","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.216671","volume":"131","author":"C Zhang","year":"2018","unstructured":"Zhang C, Gao J, Li M, Deng Y, Jiang C. P38\u03b4 MAPK regulates aggresome biogenesis by phosphorylating SQSTM1 in response to proteasomal stress. J Cell Sci. 2018;131(14):jcs216671.","journal-title":"J Cell Sci"},{"issue":"21","key":"2472_CR292","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111376","volume":"22","author":"M Babagana","year":"2021","unstructured":"Babagana M, Brown LR, Slabodkin HZ, Kichina JV, Kandel ES. Proteotoxic stress as an exploitable vulnerability in cells with hyperactive AKT. Int J Mol Sci. 2021;22(21):11376.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2472_CR293","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","volume":"24","author":"C Leung-Hagesteijn","year":"2013","unstructured":"Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24(3):289\u2013304.","journal-title":"Cancer Cell"},{"issue":"19","key":"2472_CR294","first-page":"6174","volume":"63","author":"D Chauhan","year":"2003","unstructured":"Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes Bortezomib\/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003;63(19):6174\u20137.","journal-title":"Cancer Res."},{"issue":"1","key":"2472_CR295","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02220-1","volume":"41","author":"C Gu","year":"2022","unstructured":"Gu C, Wang Y, Zhang L, et al. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res. 2022;41(1):11.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"2472_CR296","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41419-019-1881-x","volume":"10","author":"X Zhang","year":"2019","unstructured":"Zhang X, Lin C, Song J, et al. Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-\u03baB activity in hepatocellular carcinoma. Cell Death Dis. 2019;10(10):719.","journal-title":"Cell Death Dis"},{"key":"2472_CR297","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2025.2481661","author":"HJ Kim","year":"2025","unstructured":"Kim HJ, Kim HJ, Kim SY, Roh J, Yun JH, Kim CH. TBK1 is a signaling hub in coordinating stress-adaptive mechanisms in head and neck cancer progression. Autophagy. 2025. https:\/\/doi.org\/10.1080\/15548627.2025.2481661.","journal-title":"Autophagy"},{"issue":"13","key":"2472_CR298","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/onc.2013.110","volume":"33","author":"F Rapino","year":"2014","unstructured":"Rapino F, Jung M, Fulda S. BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways. Oncogene. 2014;33(13):1713\u201324.","journal-title":"Oncogene"},{"issue":"1","key":"2472_CR299","doi-asserted-by":"publisher","first-page":"e22121","DOI":"10.1096\/fj.202101342RR","volume":"36","author":"C Zhang","year":"2022","unstructured":"Zhang C, Tang Q, Xia H, Xu H, Bi F. PKM2 compensates for proteasome dysfunction by mediating the formation of the CHIP-HSP70-BAG3 complex and the aggregation of ubiquitinated proteins. FASEB J. 2022;36(1):e22121.","journal-title":"FASEB J"},{"issue":"18","key":"2472_CR300","doi-asserted-by":"publisher","first-page":"7169","DOI":"10.1074\/jbc.AC119.008036","volume":"294","author":"J Xie","year":"2019","unstructured":"Xie J, Van Damme P, Fang D, Proud CG. Ablation of elongation factor 2 kinase enhances heat-shock protein 90 chaperone expression and protects cells under proteotoxic stress. J Biol Chem. 2019;294(18):7169\u201376.","journal-title":"J Biol Chem"},{"issue":"4","key":"2472_CR301","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1002\/cam4.5250","volume":"12","author":"MV Mateos","year":"2023","unstructured":"Mateos MV, Prosper F, Martin S\u00e1nchez J, et al. Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Cancer Med. 2023;12(4):3999\u20134009.","journal-title":"Cancer Med"},{"issue":"3","key":"2472_CR302","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.chembiol.2021.08.011","volume":"29","author":"R Kunder","year":"2022","unstructured":"Kunder R, Velyunskiy M, Dunne SF, et al. Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. Cell Chem Biol. 2022;29(3):358-372.e5.","journal-title":"Cell Chem Biol."},{"issue":"3","key":"2472_CR303","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031341","volume":"22","author":"SW Lee","year":"2021","unstructured":"Lee SW, Yeon SK, Kim GW, et al. Hdac6-selective inhibitor overcomes bortezomib resistance in multiple myeloma. Int J Mol Sci. 2021;22(3):1341.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2472_CR304","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052576","volume":"7","author":"H Huang","year":"2012","unstructured":"Huang H, Liu N, Yang C, et al. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo. PLoS One. 2012;7(12):e52576.","journal-title":"PLoS One"},{"issue":"1","key":"2472_CR305","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13046-024-03071-2","volume":"43","author":"E Su\u00e1rez-Mart\u00ednez","year":"2024","unstructured":"Su\u00e1rez-Mart\u00ednez E, Piersma SR, Pham TV, Bijnsdorp IV, Jimenez CR, Carnero A. Protein homeostasis maintained by HOOK1 levels promotes the tumorigenic and stemness properties of ovarian cancer cells through reticulum stress and autophagy. J Exp Clin Cancer Res. 2024;43(1):150.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2472_CR306","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/15384101.2018.1558870","volume":"18","author":"L Chen","year":"2019","unstructured":"Chen L, Yang X. TRIM11 cooperates with HSF1 to suppress the anti-tumor effect of proteotoxic stress drugs. Cell Cycle. 2019;18(1):60\u20138.","journal-title":"Cell Cycle"},{"key":"2472_CR307","doi-asserted-by":"crossref","unstructured":"Gong C, Krupka JA, Gao J, et al. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Mol Cell. 2021;81(19):4059\u20134075.e11.","DOI":"10.1016\/j.molcel.2021.07.041"},{"issue":"17","key":"2472_CR308","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/onc.2016.392","volume":"36","author":"K Chroma","year":"2017","unstructured":"Chroma K, Mistrik M, Moudry P, et al. Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress. Oncogene. 2017;36(17):2405\u201322.","journal-title":"Oncogene"},{"issue":"8","key":"2472_CR309","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.72","volume":"6","author":"T Avril","year":"2017","unstructured":"Avril T, Vaul\u00e9on E, Chevet E. Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers. Oncogenesis. 2017;6(8):e373.","journal-title":"Oncogenesis"},{"key":"2472_CR310","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120852","volume":"306","author":"A Hasan","year":"2022","unstructured":"Hasan A, Rizvi SF, Parveen S, Mir SS. Molecular chaperones in DNA repair mechanisms: role in genomic instability and proteostasis in cancer. Life Sci. 2022;306:120852.","journal-title":"Life Sci"},{"issue":"1","key":"2472_CR311","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/boc.201800050","volume":"111","author":"E Madden","year":"2019","unstructured":"Madden E, Logue SE, Healy SJ, Manie S, Samali A. The role of the unfolded protein response in cancer progression: from oncogenesis to chemoresistance. Biol Cell. 2019;111(1):1\u201317.","journal-title":"Biol Cell"},{"issue":"4","key":"2472_CR312","doi-asserted-by":"publisher","first-page":"842","DOI":"10.20892\/j.issn.2095-3941.2020.0005","volume":"17","author":"YJ Chern","year":"2020","unstructured":"Chern YJ, Tai IT. Adaptive response of resistant cancer cells to chemotherapy. Cancer Biol Med. 2020;17(4):842\u201363.","journal-title":"Cancer Biol Med"},{"issue":"3","key":"2472_CR313","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030338","volume":"11","author":"E Bahar","year":"2019","unstructured":"Bahar E, Kim JY, Yoon H. Chemotherapy resistance explained through endoplasmic reticulum stress-dependent signaling. Cancers (Basel). 2019;11(3):338.","journal-title":"Cancers (Basel)"},{"key":"2472_CR314","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1500880","volume":"12","author":"S Ghai","year":"2025","unstructured":"Ghai S, Shrestha R, Su KH. HSF1 at the crossroads of chemoresistance: from current insights to future horizons in cell death mechanisms. Front Cell Dev Biol. 2025;12:1500880.","journal-title":"Front Cell Dev Biol"},{"issue":"21","key":"2472_CR315","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215167","volume":"15","author":"KE Gumilar","year":"2023","unstructured":"Gumilar KE, Chin Y, Ibrahim IH, et al. Heat shock factor 1 inhibition: a novel anti-cancer strategy with promise for precision oncology. Cancers (Basel). 2023;15(21):5167.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2472_CR316","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.2174\/1871520618666180817114952","volume":"18","author":"Z Krawczyk","year":"2018","unstructured":"Krawczyk Z, Gogler-Pig\u0142owska A, Sojka DR, Scieglinska D. The role of heat shock proteins in Cisplatin resistance. Anticancer Agents Med Chem. 2018;18(15):2093\u2013109.","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"2472_CR317","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010060","volume":"9","author":"CW Yun","year":"2019","unstructured":"Yun CW, Kim HJ, Lim JH, Lee SH. Heat shock proteins: agents of cancer development and therapeutic targets in anti-cancer therapy. Cells. 2019;9(1):60.","journal-title":"Cells"},{"issue":"1","key":"2472_CR318","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0021-9258(19)40219-6","volume":"265","author":"KV Chin","year":"1990","unstructured":"Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem. 1990;265(1):221\u20136.","journal-title":"J Biol Chem"},{"issue":"1","key":"2472_CR319","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0014-5793(92)80205-U","volume":"301","author":"N Kioka","year":"1992","unstructured":"Kioka N, Yamano Y, Komano T, Ueda K. Heat-shock responsive elements in the induction of the multidrug resistance gene (MDR1). FEBS Lett. 1992;301(1):37\u201340.","journal-title":"FEBS Lett"},{"issue":"32","key":"2472_CR320","doi-asserted-by":"publisher","first-page":"24970","DOI":"10.1074\/jbc.M909136199","volume":"275","author":"NE Vilaboa","year":"2000","unstructured":"Vilaboa NE, Gal\u00e1n A, Troyano A, de Blas E, Aller P. Regulation of multidrug resistance 1 (MDR1)\/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J Biol Chem. 2000;275(32):24970\u20136.","journal-title":"J Biol Chem"},{"key":"2472_CR321","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.620907","volume":"11","author":"L Yin","year":"2021","unstructured":"Yin L, Yang Y, Zhu W, et al. Heat shock protein 90 triggers multi-drug resistance of ovarian cancer via AKT\/GSK3\u03b2\/\u03b2-catenin signaling. Front Oncol. 2021;11:620907.","journal-title":"Front Oncol"},{"key":"2472_CR322","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-504","volume":"13","author":"N Vydra","year":"2013","unstructured":"Vydra N, Toma A, Glowala-Kosinska M, Gogler-Piglowska A, Widlak W. Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel. BMC Cancer. 2013;13:504.","journal-title":"BMC Cancer"},{"issue":"4","key":"2472_CR323","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/1878-0261.12883","volume":"15","author":"R Lombardi","year":"2021","unstructured":"Lombardi R, Sonego M, Pucci B, et al. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer. Mol Oncol. 2021;15(4):1005\u201323.","journal-title":"Mol Oncol"},{"issue":"5","key":"2472_CR324","first-page":"6687","volume":"8","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Xie Z, Sun G, et al. Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cells. Int J Clin Exp Med. 2015;8(5):6687\u2013701.","journal-title":"Int J Clin Exp Med."},{"issue":"24","key":"2472_CR325","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246163","volume":"13","author":"KM Ewers","year":"2021","unstructured":"Ewers KM, Patil S, Kopp W, et al. HSP90 inhibition synergizes with cisplatin to eliminate basal-like pancreatic ductal adenocarcinoma cells. Cancers (Basel). 2021;13(24):6163.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2472_CR326","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/ijc.32227","volume":"145","author":"GP Nagaraju","year":"2019","unstructured":"Nagaraju GP, Zakka KM, Landry JC, Shaib WL, Lesinski GB, El-Rayes BF. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. Int J Cancer. 2019;145(6):1529\u201337.","journal-title":"Int J Cancer"},{"issue":"13","key":"2472_CR327","doi-asserted-by":"publisher","first-page":"9165","DOI":"10.1074\/jbc.M112.422071","volume":"288","author":"S Desai","year":"2013","unstructured":"Desai S, Liu Z, Yao J, et al. Heat shock factor 1 (HSF1) controls chemoresistance and autophagy through transcriptional regulation of autophagy-related protein 7 (ATG7). J Biol Chem. 2013;288(13):9165\u201376.","journal-title":"J Biol Chem"},{"issue":"7","key":"2472_CR328","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12272-023-01455-0","volume":"46","author":"YJ Kim","year":"2023","unstructured":"Kim YJ, Lee Y, Shin H, Hwang S, Park J, Song EJ. Ubiquitin-proteasome system as a target for anticancer treatment-an update. Arch Pharm Res. 2023;46(7):573\u201397.","journal-title":"Arch Pharm Res"},{"issue":"6","key":"2472_CR329","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061235","volume":"13","author":"T Paradzik","year":"2021","unstructured":"Paradzik T, Bandini C, Mereu E, et al. The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma. Cancers (Basel). 2021;13(6):1235.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2472_CR330","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27072201","volume":"27","author":"C Leonardo-Sousa","year":"2022","unstructured":"Leonardo-Sousa C, Carvalho AN, Guedes RA, et al. Revisiting proteasome inhibitors: molecular underpinnings of their development, mechanisms of resistance and strategies to overcome anti-cancer drug resistance. Molecules. 2022;27(7):2201.","journal-title":"Molecules"},{"issue":"7","key":"2472_CR331","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","volume":"14","author":"EE Manasanch","year":"2017","unstructured":"Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14(7):417\u201333.","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"2472_CR332","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.2174\/1381612811319220015","volume":"19","author":"L Gatti","year":"2013","unstructured":"Gatti L, Zuco V, Zaffaroni N, Perego P. Drug combinations with proteasome inhibitors in antitumor therapy. Curr Pharm Des. 2013;19(22):4094\u2013114.","journal-title":"Curr Pharm Des"},{"issue":"6662","key":"2472_CR333","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn4180","volume":"381","author":"X Lv","year":"2023","unstructured":"Lv X, Lu X, Cao J, et al. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science. 2023;381(6662):eabn4180.","journal-title":"Science"},{"key":"2472_CR334","doi-asserted-by":"crossref","unstructured":"Zhou C, Li C, Luo L, et al. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer Cell. 2024;42(7):1286\u20131300.e8.","DOI":"10.1016\/j.ccell.2024.06.001"},{"key":"2472_CR335","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117866","author":"A Paik","year":"2025","unstructured":"Paik A, Purawarga Matada GS, Ghara A, Pal R, Pavani G, Kamurthy H. BRAF inhibitors in melanoma: structural insights, therapeutic resistance, and biological evaluation of quinazoline derivatives. Eur J Med Chem. 2025. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117866.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"2472_CR336","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00207-x","volume":"5","author":"Y Qin","year":"2021","unstructured":"Qin Y, Zuo Q, Huang L, Huang L, Merlino G, Yu Y. Perk mediates resistance to BRAF inhibition in melanoma with impaired PTEN. NPJ Precis Oncol. 2021;5(1):68.","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"2472_CR337","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/mc.23407","volume":"61","author":"J Jandova","year":"2022","unstructured":"Jandova J, Park SL, Corenblum MJ, et al. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAFV600E\/NRASQ61K malignant melanoma cells targeting intracranial tumors in a bioluminescent murine model. Mol Carcinog. 2022;61(6):603\u201314.","journal-title":"Mol Carcinog"},{"issue":"3","key":"2472_CR338","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CMR.0000000000000734","volume":"31","author":"JN Sanchez","year":"2021","unstructured":"Sanchez JN, Subramanian C, Chanda M, et al. A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas. Melanoma Res. 2021;31(3):197\u2013207.","journal-title":"Melanoma Res"},{"issue":"5","key":"2472_CR339","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s10565-022-09729-x","volume":"39","author":"T Wu","year":"2023","unstructured":"Wu T, Li C, Zhou C, et al. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2. Cell Biol Toxicol. 2023;39(5):2381\u201399.","journal-title":"Cell Biol Toxicol"},{"issue":"18","key":"2472_CR340","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1038\/s41388-019-0675-z","volume":"38","author":"D Wang","year":"2019","unstructured":"Wang D, Xu Q, Yuan Q, et al. Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab. Oncogene. 2019;38(18):3458\u201374.","journal-title":"Oncogene"},{"issue":"6","key":"2472_CR341","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0691-x","volume":"9","author":"A Yallowitz","year":"2018","unstructured":"Yallowitz A, Ghaleb A, Garcia L, Alexandrova EM, Marchenko N. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells. Cell Death Dis. 2018;9(6):621.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2472_CR342","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","volume":"9","author":"X Du","year":"2018","unstructured":"Du X, Shao Y, Qin HF, Tai YH, Gao HJ. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer. 2018;9(4):423\u201330.","journal-title":"Thorac Cancer."},{"issue":"5","key":"2472_CR343","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1158\/1078-0432.CCR-20-2853","volume":"27","author":"A Tanimoto","year":"2021","unstructured":"Tanimoto A, Matsumoto S, Takeuchi S, et al. Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged\/TP53-Mutant NSCLC via Noxa Expression. Clin Cancer Res. 2021;27(5):1410\u201320.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2472_CR344","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10565-024-09979-x","volume":"41","author":"C Huang","year":"2025","unstructured":"Huang C, Zhang C, Li J, Duan Y, Tang Q, Bi F. Targeting p38\u03b3 synergistically enhances sorafenib-induced cytotoxicity in hepatocellular carcinoma. Cell Biol Toxicol. 2025;41(1):35.","journal-title":"Cell Biol Toxicol."},{"key":"2472_CR345","doi-asserted-by":"crossref","unstructured":"Prieto-Dom\u00ednguez N, Ord\u00f3\u00f1ez R, Fern\u00e1ndez A, et al. Modulation of Autophagy by Sorafenib: Effects on Treatment Response. Front Pharmacol. 2016;7:151.","DOI":"10.3389\/fphar.2016.00151"},{"issue":"10","key":"2472_CR346","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41419-019-1989-z","volume":"10","author":"J Gavini","year":"2019","unstructured":"Gavini J, Dommann N, Jakob MO, et al. Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. Cell Death Dis. 2019;10(10):749.","journal-title":"Cell Death Dis."},{"issue":"43","key":"2472_CR347","doi-asserted-by":"publisher","first-page":"73947","DOI":"10.18632\/oncotarget.18166","volume":"8","author":"RL Carpenter","year":"2017","unstructured":"Carpenter RL, Sirkisoon S, Zhu D, et al. Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Oncotarget. 2017;8(43):73947\u201363.","journal-title":"Oncotarget."},{"key":"2472_CR348","doi-asserted-by":"crossref","unstructured":"Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14(12):2994\u20133006.","DOI":"10.1002\/1878-0261.12851"},{"issue":"10","key":"2472_CR349","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.ccell.2022.08.016","volume":"40","author":"JK Mandula","year":"2022","unstructured":"Mandula JK, Chang S, Mohamed E, et al. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses. Cancer Cell. 2022;40(10):1145-1160.e9.","journal-title":"Cancer Cell."},{"key":"2472_CR350","doi-asserted-by":"crossref","unstructured":"Benvenuto M, Ciuffa S, Focaccetti C, et al. Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells. Sci Rep. 2021;11(1):19051.","DOI":"10.1038\/s41598-021-98450-6"},{"key":"2472_CR351","doi-asserted-by":"crossref","unstructured":"Maione F, Oddo D, Galvagno F, et al. Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models. Mol Oncol. 2024;18(6):1552\u20131570.","DOI":"10.1002\/1878-0261.13595"},{"key":"2472_CR352","doi-asserted-by":"crossref","unstructured":"Batista A, Rodvold JJ, Xian S, et al. IRE1\u03b1 regulates macrophage polarization, PD-L1 expression, and tumor survival. PLoS Biol. 2020;18(6):e3000687.","DOI":"10.1371\/journal.pbio.3000687"},{"key":"2472_CR353","doi-asserted-by":"crossref","unstructured":"Ma J, Tan J, Zhang W, Bai M, Liu K. Prenatal inflammation exposure accelerates lung cancer tumorigenesis in offspring mouse: possible links to IRE1\u03b1\/XBP1-mediated M2-like polarization of TAMs and PD-L1 up-expression. Cancer Immunol Immunother. 2024;73(5):88.","DOI":"10.1007\/s00262-024-03666-w"},{"key":"2472_CR354","doi-asserted-by":"crossref","unstructured":"Zhou Q, Liang J, Yang T, et al. Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO Mol Med. 2022;14(1):e14502.","DOI":"10.15252\/emmm.202114502"},{"key":"2472_CR355","doi-asserted-by":"crossref","unstructured":"Nikotina AD, Vladimirova SA, Kokoreva NE, et al. Novel mechanism of drug resistance triggered by tumor-associated macrophages through Heat Shock Factor-1 activation. Cancer Immunol Immunother. 2024;73(2):25.","DOI":"10.1007\/s00262-023-03612-2"},{"key":"2472_CR356","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.2147\/DDDT.S267433","volume":"14","author":"L Ai","year":"2020","unstructured":"Ai L, Chen J, Yan H, et al. Research Status and Outlook of PD-1\/PD-L1 Inhibitors for Cancer Therapy. Drug Des Devel Ther. 2020;14:3625\u201349.","journal-title":"Drug Des Devel Ther."},{"key":"2472_CR357","doi-asserted-by":"crossref","unstructured":"Zavareh RB, Spangenberg SH, Woods A, Mart\u00ednez-Pe\u00f1a F, Lairson LL. HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins. Cell Chem Biol. 2021;28(2):158\u2013168.e5.","DOI":"10.1016\/j.chembiol.2020.10.005"},{"key":"2472_CR358","doi-asserted-by":"crossref","unstructured":"Liu K, Huang J, Liu J, et al. HSP90 Mediates IFN\u03b3-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy. Cancer Res. 2022;82(10):2003\u20132018.","DOI":"10.1158\/0008-5472.CAN-21-3917"},{"key":"2472_CR359","doi-asserted-by":"crossref","unstructured":"Mehndiratta S, Lin MH, Wu YW, et al. N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-\u03b3 induced PD-L1 expression [published correction appears in Eur J Med Chem. 2020;199:112406.","DOI":"10.1016\/j.ejmech.2020.112406"},{"key":"2472_CR360","doi-asserted-by":"publisher","first-page":"1005045","DOI":"10.3389\/fimmu.2022.1005045","volume":"13","author":"S Rahmy","year":"2022","unstructured":"Rahmy S, Mishra SJ, Murphy S, Blagg BSJ, Lu X. Hsp90\u03b2 inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors. Front Immunol. 2022;13:1005045.","journal-title":"Front Immunol."},{"issue":"20","key":"2472_CR361","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1158\/0008-5472.CAN-19-0063","volume":"79","author":"T Yang","year":"2019","unstructured":"Yang T, Ren C, Lu C, et al. Phosphorylation of HSF1 by PIM2 induces PD-L1 expression and promotes tumor growth in breast cancer. Cancer Res. 2019;79(20):5233\u201344.","journal-title":"Cancer Res"},{"issue":"1","key":"2472_CR362","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12964-021-00810-2","volume":"20","author":"Y Yuan","year":"2022","unstructured":"Yuan Y, Jiao P, Wang Z, et al. Endoplasmic reticulum stress promotes the release of exosomal PD-L1 from head and neck cancer cells and facilitates M2 macrophage polarization. Cell Commun Signal. 2022;20(1):12.","journal-title":"Cell Commun Signal."},{"issue":"8","key":"2472_CR363","first-page":"2621","volume":"10","author":"CW Chou","year":"2020","unstructured":"Chou CW, Yang RY, Chan LC, et al. The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer. Am J Cancer Res. 2020;10(8):2621\u201334.","journal-title":"Am J Cancer Res."},{"issue":"12","key":"2472_CR364","doi-asserted-by":"publisher","first-page":"30405","DOI":"10.3390\/ijms161226238","volume":"16","author":"E Cacan","year":"2015","unstructured":"Cacan E, Spring AM, Kumari A, Greer SF, Garnett-Benson C. Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack. Int J Mol Sci. 2015;16(12):30405\u201321.","journal-title":"Int J Mol Sci."},{"issue":"3","key":"2472_CR365","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3892\/ijo.2013.1786","volume":"42","author":"T Tamatani","year":"2013","unstructured":"Tamatani T, Takamaru N, Hara K, et al. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-\u03baB activity in human oral cancer cells. Int J Oncol. 2013;42(3):935\u201344.","journal-title":"Int J Oncol"},{"key":"2472_CR366","doi-asserted-by":"crossref","unstructured":"Kern J, Schilling D, Schneeweis C, et al. Identification of the unfolded protein response pathway as target for radiosensitization in pancreatic cancer. Radiother Oncol. 2024;191:110059.","DOI":"10.1016\/j.radonc.2023.110059"},{"issue":"28","key":"2472_CR367","doi-asserted-by":"publisher","first-page":"43199","DOI":"10.18632\/oncotarget.9774","volume":"7","author":"L Kinzel","year":"2016","unstructured":"Kinzel L, Ernst A, Orth M, et al. A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer. Oncotarget. 2016;7(28):43199\u2013219.","journal-title":"Oncotarget."},{"key":"2472_CR368","doi-asserted-by":"crossref","unstructured":"Kim YM, Pyo H. Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines. DNA Cell Biol. 2012;31(1):15\u201329.","DOI":"10.1089\/dna.2011.1342"},{"issue":"3","key":"2472_CR369","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.bbrc.2006.10.094","volume":"351","author":"M Noguchi","year":"2006","unstructured":"Noguchi M, Yu D, Hirayama R, et al. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem Biophys Res Commun. 2006;351(3):658\u201363.","journal-title":"Biochem Biophys Res Commun."},{"key":"2472_CR370","doi-asserted-by":"crossref","unstructured":"Dungey FA, Caldecott KW, Chalmers AJ. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther. 2009;8(8):2243\u20132254.","DOI":"10.1158\/1535-7163.MCT-09-0201"},{"key":"2472_CR371","doi-asserted-by":"crossref","unstructured":"Gu C, Zhang J, Gao W, et al. Advances and applications of hyperthermia in tumor therapy: Mechanisms, techniques, and clinical integration. International Communications in Heat and Mass Transfer. 2025; 164:108895.","DOI":"10.1016\/j.icheatmasstransfer.2025.108895"},{"key":"2472_CR372","doi-asserted-by":"crossref","unstructured":"Chen O, Michl\u00edkov\u00e1 S, Eckhardt L, et al. Efficient Heat Shock Response Affects Hyperthermia-Induced Radiosensitization in a Tumor Spheroid Control Probability Assay. Cancers (Basel). 2021;13(13):3168.","DOI":"10.3390\/cancers13133168"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02472-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02472-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02472-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:04:05Z","timestamp":1761051845000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02472-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":372,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2472"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02472-x","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"265"}}